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Primary headaches are headache disorders that do not result from another medical 
condition but are independent entities with different, although still not completely 
understood, pathophysiological mechanisms. Primary headaches include migraine, 
tension-type headache (TTH), trigeminal autonomic cephalalgias (TACs) and a 
rather heterogeneous group termed other primary headache disorders. These four 
large categories consist of numerous diverse headache subtypes and distinct 
diagnostic entities (Headache Classification Committee of the International 
Headache Society, 2018). 
Primary headaches do not only cause considerable personal suffering and loss 
of quality of life but are a significant public health issue and a source of remark-
able societal burden (Steiner et al, 2014; Global Burden of Disease, 2015; Messali 
et al, 2016; Saylor and Steiner, 2018). Migraine and TTH are both among the top 
six most prevalent diseases in the world and migraine is the second leading cause 
of years lived with disability globally (Vos et al, 2017). 
Epidemiological studies create the basis for the assessment of disease patterns, 
burden, cost and need for health services in society (Steiner et al, 2013; Stovner 
et al, 2014). The epidemiological data on primary headaches have been steadily 
growing in the last two decades worldwide (Stovner et al, 2007; Stovner and 
Andree, 2010; World Health Organization and Lifting The Burden, 2011; Saylor 
and Steiner, 2018). However, in some regions, like in Eastern Europe, gaps are 
still notable. The prevalence of primary headaches in Estonia has not been studied 
previously. 
Large population-based epidemiological studies are usually resource and time 
consuming (Stovner et al, 2014). In the face of rapid digital evolution it would be 
beneficial to search for new methods for epidemiological surveys that could 
exploit the contemporary fast development of information technology. It certainly 
could be the case in headache epidemiology, bearing in mind that most primary 
headaches can be diagnosed based on history and do not require additional 
instrumental investigations (Mitsikostas et al, 2017). 
Estonia is one of the leading countries in the world regarding the usage of 
internet and web-based solutions per household (International Telecommu-
nication Union, 2017). In 2019 Estonia ranked 8th out of the 28 European Union 
Member States in the European Commission Digital Economy and Society Index, 
a composite index that summarises relevant indicators on member states’ digital 
performance, showing that the use of internet services remains consistently high 
in this country (European Commission, 2019). The digital economy and society 
index comprises, among other aspects, connectivity, human digital inclusion and 
skills, use of internet services, integration of digital technology and digital public 
services. The aforementioned aspects set up potentially promising conditions for 
using e-technology in performing representative studies in headache epidemio-
logy in Estonia. 
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2. REVIEW OF THE LITERATURE 
2.1 Classification of primary headaches 
Today headache is one of the most thoroughly classified neurological diseases. 
The first edition of International Classification of Headache Disorders (ICHD) 
was published in 1988. It was primarily based on the opinions of experts and the 
main purpose of it was to establish operational diagnostic criteria for different 
headache disorders to enable and increase nosographic and epidemiologic 
research. The authors readily admitted, and in fact it was one of its goals, that 
extensive studies must be conducted to make the classification more evidence-
based (Headache Classification Committee of the International Headache Society, 
1988). The first edition of ICHD was followed by the second in 2004 and it 
included changes prompted by new evidence and revised opinions of experts 
(Headache Classification Subcommittee of the International Headache Society, 
2004). The latest ICHD third edition (Headache Classification Committee of the 
International Headache Society, 2018) was preceded by a beta version in 2013 
(Headache Classification Committee of the International Headache Society, 
2013). The idea behind this beta version was to allow more field testing before 
publication of the final ICHD-3 in 2018, and as the authors concluded, had 
worked well since new scientific evidence played a significantly increasing role 
in the changes made in ICHD-3. 
Both the ICHD-3 beta and ICHD-3 consist of three parts – the primary 
headaches, the secondary headaches and thirdly painful cranial neuropathies, 
other facial pains and other headaches. 
The first part, primary headaches, consists of four major entities: migraine, 
tension-type headache, TACs and other primary headache disorders. These 
disorders are further subclassified hierarchically, giving the possibility to make a 
headache diagnosis with relevant degree of detail, ranging from the general first-
digit level to the most detailed fifth-digit level diagnosis. 
In epidemiological studies the diagnoses are usually made with second-digit 
accuracy, with some specific deliberations related to the nature of epidemio-
logical research (Stovner et al, 2014). The ICHD second-digit level diagnoses for 
migraine and TTH that are important from the epidemiological research 
perspective are migraine with or without aura, chronic migraine, probable 
migraine, frequent episodic tension-type headache, chronic tension-type headache 
and probable tension-type headache. TACs and other primary headache disorders 
are rare entities with numerous subdivisions. The TACs’ second-digit level 
diagnoses include cluster headache (CH), paroxysmal hemicrania, short-lasting 
unilateral neuralgiform headache attacks, hemicrania continua and probable 
TACs. The other primary headache disorders include the following ten second-
digit level diagnoses: primary cough headache, primary exercise headache, 
primary headache associated with sexual activity, primary thunderclap headache, 
cold-stimulus headache, external-pressure headache, primary stabbing headache, 
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nummular headache, hypnic headache and new daily persistent headache 
(NDPH) (Headache Classification Committee of the International Headache 
Society, 2013 and 2018). 
 
 
2.2 Methodology of population surveys of headache 
prevalence 
For the last two decades the recognition of the magnitude of the impact of 
headaches on personal as well as societal level has been steadily growing (Steiner 
et al, 2014; Global Burden of Disease, 2015; Messali et al, 2016; Saylor and 
Steiner, 2018). This has largely stemmed from the increasing evidence on 
headache epidemiology. However, several reviews of the world literature on the 
topic (Stovner et al, 2006; Stovner et al, 2007, Stovner and Andree, 2010) showed 
significant variations and a number of shortcomings in the methodology of 
headache epidemiology studies and the need for standardized approach became 
evident (Steiner et al, 2013). Lifting The Burden, a United Kingdom non-profit 
organization in official relations with World Health Organization (Steiner et al, 
2011) with the priority to fill the knowledge gaps of headache epidemiology and 
burden (Saylor and Steiner, 2018), engaged an expert panel to develop consensus 
guidelines on the principles of conduct of cross-sectional population-based 
studies of headache. The guidelines were published in 2014 (Stovner et al, 2014) 
and the detailed document includes recommendations with extensive explanatory 
commentary on ethical issues, study design, population of interest, control of 
bias, sample selection and avoidance of selection bias, accessing and engaging 
participants, participation rate and non-participation, method of enquiry, case 
definition and diagnosis, aspects of pilot study, data collection and storage and 
reporting the study. In addition, the authors proposed criteria and a scoring system 
for evaluating the quality of headache prevalence studies. Very shortly and in 
general, a headache prevalence study of good quality should be conducted on 
general population or community-based sample from defined region within a 
country, has a random sample corrected for population demographics, has a 
number of respondents >1500, has a participation rate of >70%, accesses the 
participants by telephone or face-to-face interview by trained interviewers, has a 
validated diagnostic instrument with sensitivity and specificity >70%, uses ICHD 
diagnostic criteria and has a prevalence time frame of specified period 
appropriate to the study purpose (mostly point, one-year or lifetime prevalence) 
(Stovner et al, 2014). 
 
 
2.2.1 Headache diagnoses in headache epidemiology research 
In all epidemiologic studies, it is of fundamental importance to define caseness, 
in other words who has a certain diagnosis and who has not (Stovner et al, 2006; 
Stovner et al, 2014). The aforementioned consensus guidelines of population 
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surveys of headache prevalence (Stovner et al, 2014) stipulate that all the studies 
should use the most recent ICHD criteria for determining headache cases. 
However, the authors agree that since the ICHD criteria were not designed for 
epidemiological studies, several justified deliberations are inevitable. For 
example, it is recommended not to distinguish between migraine with and without 
aura, because it is nearly impossible to diagnose aura by a questionnaire (Stovner 
et al, 2007; Stovner and Andree, 2010, Stovner et al, 2014). When speaking about 
headache occurring on ≥15 days per month, it is acceptable not to differentiate 
further if it is a chronic TTH, chronic migraine or any other type of chronic 
headache, since it is recognized that precise diagnosis is difficult at an one-time 
encounter with the study subject (Stovner et al, 2014). The synonymously used 
terms „headache on ≥15 days per month“, „chronic headache“ or „chronic daily 
headache“ are not independent entities defined in ICHD (Headache Classification 
Committee of the International Headache Society, 1988, 2004, 2013 and 2018), 
however, these terms refer to a subset of headache disorders that are most 
incapacitating, have a severe socioeconomical impact and thus are an important 
issue in headache epidemiology research (Stovner et al, 2007; Stovner and 
Andree, 2010; Steiner et al, 2013; Stovner et al, 2014; Global Burden of Disease, 
2015; Messali et al, 2016). Many epidemiological studies also incorporate 
medication overuse headache (MOH) for the same reason (Stovner and Andree, 
2010; Stovner et al, 2014, Saylor and Steiner, 2018), although MOH is not a 
primary headache, but a secondary one developing as a consequence of regular 
overuse of acute headache medication (Headache Classification Committee of the 
International Headache Society, 2004, 2013 and 2018; Vandenbussche et al, 
2018). Large population-based surveys usually do not study other secondary 
headaches because reasonably certain diagnosis of a secondary headache requires 
extensive clinical and medical investigations, and often follow-up, which is not 




2.2.2 Timeframe of headache in headache epidemiology research 
The most widely used timeframe in headache epidemiology research has been 
one-year prevalence (Stovner et al, 2007; Stovner and Andree, 2010, Steiner et 
al, 2013; Stovner et al, 2014) and therefore allows the most comparisons with 
other studies. This corresponds to the term „active headache disorder“ defined in 
ICHD-2 and characterized by any occurrence of headache during the last year 
(Headache Classification Committee of the International Headache Society, 
2004; Stovner et al, 2014). However, this timeframe is not free from recall bias 
and thus very short and recent timeframes have been applied – 1-day prevalence, 
or „headache today/yesterday“ (Yu et al, 2013; Andree et al, 2014; Stovner et al, 
2014; Ayzenberg et al, 2015, Steiner et al, 2016). These avoid recall bias almost 
entirely, but do not describe the whole proportion of population with an active 
headache disorder as one-year prevalence does (Stovner et al, 2014). The longest 
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timeframe, lifetime prevalence, has also been quite widely implemented (Stovner 
et al, 2007; Stovner and Andree, 2010), but is expectedly most vulnerable to 
recall bias. Lifetime prevalence is of most interest in rare headache disorders and 
also in genetic epidemiological studies, in the latter to eliminate those who have 
ever had the disorder from control groups (Stovner et al, 2014). 
 
 
2.3 Prevalence of headache in general 
2.3.1 Europe 
A review article on the prevalence of headache in Europe published in 2010 
(Stovner et al, 2010) found the one-year prevalence of all headache among adults 
in Europe to be 53%, ranging from 29% in Greece (Mitsikostas et al, 1996) to 
76% in United Kingdom (Boardman et al, 2005), and the lifetime prevalence of 
headache in Europe to be 77%, ranging from 35% in France (Henry et al, 1992) 
to 96% in Denmark (Rasmussen et al, 1991). The review covered 49 studies, 
among which 21 studies on adult populations from different European countries 
presented one-year and lifetime prevalences on headache in general (Waters et 
al, 1975; Crisp et al, 1977; Nikiforow et al, 1981; D’Alessandro et al, 1988; 
Rasmussen et al, 1991; Henry et al, 1992; Gobel et al, 1994; Laínez et al, 1994; 
Pereira Monteiro et al, 1995; Mitsikostas et al, 1996; Hagen et al, 2000; Dahlof 
and Linde, 2001; Zivadinov et al, 2001 and 2003; Boardman et al, 2003 and 2005; 
Lampl et al, 2003; Boru et al, 2005; Russell et al, 2008; Katsarava et al, 2009; 
Radke et al, 2009). The authors explained the large variations in prevalence 
estimates by methodological differences between studies. Another study 
conducted in Italy and published in 2009 but not included in the previous review, 
found a lifetime prevalence of all primary headaches combined at 52% 
(Schwaiger et al, 2009). 
A cross-sectional study conducted by the Eurolight Project of 8271 partici-
pants from selected European countries (Austria, France, Germany, Italy, 
Lithuania, Luxembourg, the Netherlands, Spain and the United Kingdom) 
published in 2014 reported an even higher gender-adjusted one-year prevalence 
of all headaches at 78.6% and a lifetime prevalence of 91.3% (Steiner et al, 2014). 
Later studies conducted by Lifting The Burden with standardized methodo-
logy (Steiner et al, 2014) in Eastern-European countries, namely Georgia 
(Katsarava et al, 2009), Lithuania (Rastenytė et al, 2017), Moldova (Moldovanu 
et al, 2007) and Russia (Ayzenberg et al, 2012), reported an one-year prevalence 







2.3.2 Other regions 
Stovner et al estimated the mean prevalence of headache in general to be close to 
50% in all other regions of the world except for Africa, where it was about 20%, 
in a review article published in 2007 (Stovner et al, 2007). This review included 
studies from all over the world and the one-year prevalences found in different 
countries from different regions other than Europe were ranging as follows: 
Africa 20–23% (Levy, 1983; Dent et al, 2004), Asia 29–79% (Sakai and Igarashi, 
1997; Roh et al, 1998; Wang et al, 2000; Deleu et al, 2002; Takeshima et al, 
2004), Australia/Oceania 50% (Paulin et al, 1985), North America 13–87% 
(O’Brien et al, 1994; Kryst and Scherl, 1994; Schwartz et al, 1997) and Central 
and South America 29–63% (Jaillard et al, 1997; Wiehe et al, 2002; Miranda et 
al, 2003). Again, large variations are evident and the same applies for the lifetime 
prevalences from the studies from the countries from different regions: Africa 
51% (Osuntokun et al, 1992), Asia 8–82% (Abduljabbar et al, 1996; Alders et al, 
1996; Sakai and Igarashi, 1997; Ho and Ong, 2003), North America 16–87% 
(Ziegler et al, 1977; Duckro et al, 1989; Kryst and Scherl, 1994; O’Brien et al, 
1994; Carson et al; 2004) and Central/South America 73–94% (Wiehe et al, 
2002; Benseñor et al, 2003). No studies were found from Australia/Oceania 
reporting lifetime prevalences. 
Since 2007, several other papers have been published, including studies 
conducted by Lifting The Burden (Saylor and Steiner, 2018). These studies have 
intentionally covered various world regions and have revealed more uniform one-
year prevalences of all headache except for the low 24% in China (Yu et al, 2012). 
The studies report one-year prevalences from India (Kulkarni et al, 2015), Nepal 
(Manandhar et al, 2015), Pakistan (Herekar et al, 2017), Ethiopia (Zebenigus et 
al, 2017), Zambia (Mbewe et al, 2015) and Saudi Arabia (Al Jumah et al, 2020) 
that range from 45–85%. It has been concluded that since the methodology of 
these studies is similar, the differences are due to other geographical, socio-
economic or genetic factors (Saylor and Steiner, 2018). 
 
 
2.4 Prevalence of migraine 
The literature on migraine prevalence is no doubt the most abundant among other 
primary headaches and the prevalence rates are more consistent compared to 
other headache disorders. Migraine is also famous for its gender difference – it is 
known to be two to three times more prevalent in women than in men (Stewart et 








Stovner et al reported a 15% (18% in females, 8% in males) mean one-year and 
a 16% (20% in females, 11% in males) lifetime prevalence of episodic migraine 
among 170,000 adults in Europe in their review article from 2010 (Stovner et al, 
2010). The calculations were based on 31 studies from different European 
countries that reported one-year prevalences ranging from 10% to 25% and 
lifetime prevalences from 9% to 28% (Rasmussen et al, 1991; Henry et al, 1992 
and 2002; Gobel et al, 1994; Laínez et al, 1994; Merikangas et al, 1994; Pereira 
Monteiro et al, 1995; Russell et al, 1995 and 2006; Michel et al, 1996; Launer et 
al, 1999; Bank et al, 2000; Hagen et al, 2000; Mattsson et al, 2000; Dahlöf and 
Linde, 2001; Zivadinov et al, 2001 and 2003; Kececi et al, 2002; Lampl et al, 
2003; Steiner et al, 2003; Boru et al, 2005; Celik et al, 2005; Lanteri-Minet et al, 
2005; Lyngberg et al, 2005; Molarius et al, 2006; Russell et al, 2008; Sjaastad 
and Bakketeig, 2008; Katsarava et al, 2009; Pfaffenrath et al, 2009; Radke et al, 
2009). The Bruneck Study from Italy published in 2009 found somewhat lower 
one-year and lifetime prevalence rates of migraine at 6% (8% in females, 3% in 
males) and 19% (29% in females, 9% in males), respectively (Schwaiger et al, 
2009). 
The later cross-sectional study by the Eurolight Project from selected 
European countries reported a higher 35% one-year prevalence of migraine (43% 
in female, 26% in male) (Steiner et al, 2014). However, studies conducted by 
Lifting The Burden (Steiner et al, 2014) in Eastern-European countries reveal 
results that are more in concordance with the aforementioned earlier studies from 
Europe, namely one-year migraine prevalences ranging from 16% in Georgia to 
20% in Russia (Moldovanu et al, 2007; Katsarava et al, 2009; Ayzenberg et al, 
2012; Rastenytė et al, 2017; Saylor and Steiner, 2018). 
 
 
2.4.2 Other regions 
In the review article by Stovner et al from 2007 it is estimated that outside Europe 
current migraine is most prevalent in the Americas (around 9–14%) and least 
prevalent in Africa (5%) (Stovner et al, 2007). The one-year prevalences of 
migraine found in countries from different regions other than Europe were 
ranging as follows: Africa 3–5% (Tekle Haimanot et al, 1995; Dent et al, 2004), 
Asia 6–22% (Alders et al, 1996; Sakai and Igarashi, 1997; Roh et al, 1998; Wang 
et al, 2000; Deleu et al, 2002; Takeshima et al, 2004), North America 9–15% 
(Stewart et al, 1992 and 1996; Kryst and Scherl, 1994; O’Brien et al, 1994; 
Schwartz et al, 1997; Lipton et al, 2001 and 2002; Patel et al, 2004) and Central 
and South America 5–14% (Jaillard et al, 1997; Lavados and Tenhamm, 1997; 
Miranda et al, 2003; Morillo et al, 2005). The more scarcely reported lifetime 
prevalences of migraine in countries from different regions were: Africa 5% 
(Osuntokun et al, 1992), Asia 3.1% (Ho et al, 2003), North America 8–17% 
(O’Brien et al, 1994; Carson et al; 2004) and Central and South America 16% 
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(Wiehe et al, 2002). No studies on migraine prevalence were found from 
Australia/Oceania (Stovner et al, 2007). 
American Migraine Prevalence and Prevention Study, a large-scale popu-
lation-based migraine prevalence study with a sample of more than 160 000 
individuals from United States conducted in 2004 but not included in the 
aforementioned review, found the one-year prevalence of all migraine to be 16% 
(females 22.6%, males 9.6%) (Lipton et al, 2007; Buse et al, 2013). 
The later studies by Lifting The Burden initiative have revealed one-year 
prevalences from China at 9% (Yu et al, 2012), India at 25% (Kulkarni et al, 
2015), Nepal at 35% (Manandhar et al, 2015), Pakistan at 22% (Herekar et al, 
2017), Ethiopia at 18% (Zebenigus et al, 2017), Zambia at 23% (Mbewe et al, 
2015) and Saudi Arabia at 25% (Al Jumah et al, 2020). 
A comprehensive review of migraine epidemiology and burden in East Asia 
published in 2019 reported an one-year migraine prevalence of 6–14% in the 
region (Takeshima et al, 2019). The study included 11 population-based studies 
in adults in China, Japan and South-Korea, four of which reported one-year 




2.5 Prevalence of TTH 
On one hand, TTH has generally been known to be the most prevalent primary 
headache disorder (Stovner et al, 2007; Steiner et al, 2014; Saylor and Steiner, 
2018). On the other, studies conducted and published on the prevalence of TTH 
are much more scarce when compared to the relative multitude of studies on 
migraine. Furthermore, different prevalence studies on TTH have revealed 
notoriously variable results (Stovner et al, 2007; Stovner and Andree, 2010). 
Possible reasons for this diversity have been suspected to lie in the differences in 
the methodological approaches across studies, diagnostic overlap of TTH with 
probable migraine, differences in headache awareness, socioeconomic, genetic or 




Stovner et al reported a mean one-year prevalence of TTH in Europe of 63% 
among more than 66 000 adults, an estimation based on nine studies in their 
review paper from 2010 (Stovner et al, 2010). The analysis included studies from 
Croatia (Zivadinov et al, 2003), Denmark (Rasmussen et al, 1991; Lyngberg et 
al, 2005; Russell et al, 2006), Georgia (Katsarava et al, 2009), Germany (Gobel 
et al, 1994; Radtke et al, 2002; Pfaffenrath et al, 2009), Portugal (Pereira 
Monteiro, 1995) and Turkey (Koseoglu et al, 2003) and the one-year and lifetime 
prevalences ranged from 19–86% and 35–78%, respectively. 
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The later cross-sectional study by the Eurolight Project from selected 
European countries reported a lower 38% one-year prevalence of TTH (Steiner 
et al, 2014) as compared to the previous review. So do the studies conducted by 
Lifting The Burden (Steiner et al, 2014) in Eastern-European countries: they 
reveal one-year prevalences of TTH ranging from 31–42% in Russia, Georgia 
and Lithuania (Katsarava et al, 2009; Ayzenberg et al, 2012; Rastenytė et al, 
2017; Saylor and Steiner, 2018) and an exceptionally low 18% in Moldova 
(Moldovanu et al, 2007). 
 
 
2.5.2 Other regions 
In the review article by Stovner et al from 2007 it was estimated that the global 
one-year prevalence of TTH is 42% and the lifetime prevalence of TTH is 46% 
(Stovner et al, 2007). These rates were based on a small number of studies from 
around the world, whereas none could be found from Africa, Australia and 
Oceania. Three studies form Asia reported one-year prevalences ranging from 
22–27% (Alders et al, 1996; Takeshima et al, 2004) and a controversial lifetime 
prevalence of 13% in Singapore (Ho and Ong, 2003), two studies from North 
America reported one-year prevalences of 20% (Pryse-Phillips et al, 1992) and 
40% (Schwartz et al, 1998) and two studies from South America reported an one-
year prevalence of 27% (Lavados and Tenhamm, 1998) and a lifetime prevalence 
of TTH of 66% (Wiehe et al, 2002). 
Studies by Lifting The Burden initiative have revealed one-year prevalences 
of TTH from China at 11% (Yu et al, 2012), India at 35% (Kulkarni et al, 2015), 
Nepal at 41% (Manandhar et al, 2015), Pakistan at 45% (Herekar et al, 2017), 
Ethiopia at 21% (Zebenigus et al, 2017), Zambia at 23% (Mbewe et al, 2015) and 
Saudi Arabia at 34% (Al Jumah et al, 2020). 
 
 
2.6 Prevalence of chronic headache 
Chronic headache or chronic daily headache, although not an independent 
diagnostic entity, includes different disorders that cause headaches on ≥15 days 
per month. Chronic headache has a significant impact on affected individuals 
personally as well as communities socioeconomically and thus is an important 
topic in headache epidemiology (Stovner et al, 2007; Stovner and Andree, 2010; 
Steiner et al, 2013; Stovner et al, 2014; Global Burden of Disease, 2015; Messali 
et al, 2016). 
Stovner et al reported a global mean one-year prevalence of chronic daily 
headache of 3.4% (Stovner et al, 2007). The estimate was based on eleven studies, 
five from Europe (Rasmussen et al, 1991; Mitsikostas et al, 1996; Castillo et al, 
1999; Hagen et al, 2000; Henry et al, 2002) and six from other regions (Tekle 
Haimanot et al, 1995; Lavados and Tenhamm, 1998; Schwartz et al, 1998; Lu 
et al, 2001; Wiehe et al, 2002; Takeshima et al, 2004) and the individual one-
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year prevalence rates of chronic headache ranged from 1.7% in Ethiopia (Tekle 
Haimanot et al, 1995) to 7.3% in Brazil (Wiehe et al, 2002). Scher et al reported 
an overall prevalence of chronic headache of 4% in a large population-based 
study in the United States (Scher et al, 1998). A later review from 2010 by 
Stovner and Andree reported a mean one-year prevalence of chronic daily 
headache in Europe of 4.0% and this review included three later studies (Wiendels 
et al, 2006; Grande et al, 2008; Katsarava et al, 2009) in addition to the five 
previously mentioned ones (Rasmussen et al, 1991; Mitsikostas et al, 1996; 
Castillo et al, 1999; Hagen et al, 2000; Henry et al, 2002). The cross-sectional 
study by the Eurolight Project from nine different European countries published 
in 2014 reported an almost two times higher 7.6% one-year prevalence of chronic 
daily headache (Steiner et al, 2014). 
The cross-sectional studies of Lifting The Burden initiative report varying 
one-year prevalence rates of headaches on ≥15 days per month (Saylor and 
Steiner, 2018), ranging from 1% in China (Yu et al, 2012) to 12% in Zambia 
(Mbewe et al, 2015). However, these seem to be consistently higher in the Eastern 
European region, where the results range from 5% in Moldova (Moldovanu et al, 
2007) to 8% in Georgia (Katsarava et al, 2009), 9% in Lithuania (Rastenytė et al, 
2017) and 10% in Russia (Ayzenberg et al, 2012). This tendency has not been 
explained, although headache on ≥ 15 days per month seems to be especially 




2.7 Prevalence of TACs 
2.7.1 Cluster headache 
CH is the most frequent TAC. A meta-analysis published in 2008 revealed a 
worldwide lifetime prevalence of CH of 0.12% and one-year prevalence of 0.05% 
(Fischera et al, 2008). It included 16 studies: eleven from Europe (Ekbom et al, 
1978; d’Alessandro et al, 1986; Rasmussen et al, 1991; Mitsikostas et al, 1994; 
Pereira Monteiro et al, 1999; Tonon et al, 2002; Sjaastad et al, 2003; Torelli et 
al, 2005; Ekbom et al, 2006; Evers et al, 2007; Katsarava et al, 2007), three from 
North-America (Swanson et al, 1994; Black et al, 2005), one from Ethiopia 
(Tekle Haimanot et al, 1995) and one from Malaysia (Alders et al, 1996). 
A later door-to-door survey in Georgia found the one-year prevalence of CH 
to be 0,09% (Katzarava et al, 2009) and a study on an urban population in Brazil 
reported a lifetime prevalence of CH of 0.04% (Jurno et al, 2018). Steinberg et 
al studied ten-year prevalence of CH among working-aged people in Sweden and 





2.7.2 Other TACs 
Since paroxysmal hemicrania, hemicrania continua and short-lasting unilateral 
neuralgiform headache attacks are very rare, there is a lack of epidemiological 
studies addressing the prevalence of these disorders in general population. 
Sjaastad et al reported finding one individual with probable paroxysmal 
hemicrania, two individuals with short-lasting unilateral neuralgiform headache 
attacks with conjunctival injection and tearing (a subform of short-lasting uni-
lateral neuralgiform headache attacks), and one individual with hemicrania 
continua in a sample of 1838 subjects of 18–65 years in the Vågå study of 
headache epidemiology in Norway (Sjaastad and Bakketeig, 2007). 
 
 
2.8 Prevalence of other primary headaches 
The epidemiological data on other primary headaches is even scarcer and the 
findings are somewhat controversial, especially for primary exercise headache 
and primary stabbing headache. 
The Bruneck Study was a prospective population-based study of the epi-
demiology of cardiovascular and neurological diseases in Italy and one of its 
goals was to evaluate the prevalence of all primary headaches in the population, 
including other primary headaches (Schwaiger et al, 2008). The authors reported 
the following one-year and lifetime prevalences, respectively – 1.7% and 2.8% 
for all other primary headaches combined, 1.2% and 1.2% for primary stabbing 
headache, 0.2% and 0.2% for primary cough headache, 0.5% and 0.2% for 
primary exercise headache, 0.5% and 0.2% for hypnic headache and 0.3% and 
<0.2% for primary thunderclap headache. They did not find any cases of primary 
headache associated with sexual activity nor of NDPH. Since cold-stimulus 
headache, external-pressure headache and nummular headache were classified as 
other primary headaches only in the later published ICHD-3 beta, these entities 
were not evaluated. 
An earlier cross-sectional study of 25–64-year-old general population con-
ducted in Denmark found the lifetime prevalence of primary stabbing headache 
to be 2%, of external pressure headache 4%, cold stimulus headache 15% and 
primary cough headache, primary exercise headache and headache associated 
with sexual activity each of 1% (Rasmussen and Olesen, 1992). 
Sjaastad and Bakketeig found the lifetime prevalence of primary exercise 
headache to be of a rather different magnitude in the Vågå study, namely 12.3% 
(Sjaastad and Bakketeig, 2002). Rabiee et al reported the one-year prevalence of 
primary exercise headache to be 7.3% in a cross-sectional study in Iran (Rabiee 
et al, 2015). Studies conducted on more specific samples of conscripts and 
cyclists have revealed even higher prevalence rates of up to 26% (van der Ende-
Kastelijn et al, 2012; Tofangchiha et al, 2016). 
The results from the prevalence studies on primary stabbing headache have 
also been contradictory – the Vågå study of headache epidemiology in Norway 
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reported the lifetime prevalence of primary stabbing headache at 35.2% (Sjaastad 
et al, 2001) as opposed to the aforementioned significantly lower prevalence 
rates. It has been proposed that the reason for this discrepancy in case of primary 
stabbing headache and primary exercise headache is the fact that both of these 
disorders are known to co-exist with other more bothersome headaches like 
migraine or CH (Drummond and Lance, 1984; Silbert et al, 1991; Pascual et al, 
2008; Hanashiro et al, 2015) and therefore are often left unnoticed (Sjaastad et 
al, 2001; Bahra, 2012). 
There are no population-based studies of the prevalence of nummular 
headache available. More than 250 cases have been reported in the literature 
(Schwartz et al, 2013). 
The one-year prevalence of NDPH in general population has been reported to 




2.9 Web-based solutions in headache research 
Online approaches in headache-related studies have started to appear in the 
literature during the last decade. Most often these are studies looking into 
headache symptoms, associated factors, treatment practices or burden. 
The web-based studies in migraine research are the most numerous. In 2016 
Messali et al published a study of direct and indirect costs of episodic and chronic 
migraine in the United States, where a web-based questionnaire was used to elicit 
data on topics related to the burden of migraine. The potential study participants 
were identified by a healthcare company from an online pool of registered 
panelists and they were screened using web-based tools to find individuals with 
migraine to be enrolled in the study (Messali et al, 2016). An analogous study 
using online approach called International Burden of Migraine Study had been 
conducted a few years earlier (Blumenfeld et al, 2011). The Migraine in America 
Symptoms and Treatment Study was a large longitudinal, internet-based panel 
study of migraine among adults in the United States. The respondents of this 
study were recruited from a nationwide online research panel and they were 
screened for migraine by a validated migraine questionnaire (Lipton et al, 2018). 
The study enabled to gather data and draw conclusions on gender differences and 
treatment patterns (Lipton et al, 2018) as well as symptoms (Dodick et al, 2019; 
Munjal et al, 2020), associated risk factors and comorbidities (Buse et al, 2020), 
acute medication overuse (Schwedt et al, 2018) and unmet acute treatment needs 
in migraine (Lipton et al, 2019). My Migraine Voice survey was a large global 
study of disease burden among individuals with migraine for whom preventive 
treatments had failed. The participants were recruited by means of existing online 
panels and support organizations for people with migraine (Martelletti et al, 
2018). Several other studies gathering data on migraine symptoms and associated 
conditions have used online survey design and the participants have been 
recruited through social media (Wachholtz et al, 2017; Hayne and Martin, 2019; 
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Gelfand et al, 2019), web apps (Drescher et al, 2019; Farris et al, 2019), migraine-
related websites (Lee et al, 2016) or specialized healthcare centers (Fragoso et al, 
2019). 
CH seems to be the second most frequent headache type that is researched 
using web-based solutions. Wilbrink et al have validated two stepwise web-based 
questionnaires (LUCA and QATCH) for diagnosing CH for carrying out large-
scale epidemiologic and genetic studies in Holland, and showed that such an 
approach would be accurate and reliable, despite the relatively low sensitivity 
values of 53.8–57.2% (Wilbrink et al, 2013). The same questionnaire was later 
used in an also web-based study of CH and depression (Louter et al, 2016). Di 
Lorenzo et al published results from an online survey of the use of illicit drugs as 
self-medication among CH patients in Italy. The participants were recruited from 
a web-based self-help group of CH patients (Di Lorenzo et al, 2016). Another 
online CH survey has also used recruiting participants from cluster headache 
websites (Schindler et al, 2018). Interictal burden of CH was assessed in the 
Eurolight Cluster Headache Project, an internet-based cross-sectional study of 
people with CH (Pohl et al, 2020). 
There are a few studies looking into other headaches besides migraine and CH. 
A web-based survey of exercise-related headache has been described by van der 
Ende-Kastelijn et al in 2012, where all the participants in a tough cycling event 
in Holland were invited to fill in an online questionnaire in order to establish the 
prevalence of primary exercise headache among an athletic population (van der 
Ende-Kastelijn et al, 2012). Bui et al studied the incidence of airplane headache 
and its potential risk factors among Scandinavian air-travellers using an online 
survey that was distributed through the Facebook-pages of Airlines and interest 
organisations (Bui et al, 2016). 
Web-based surveys have been conducted to obtain information about different 
headache treatment practices and patterns among medical professionals (Dobb 
and Cooper, 2013; Tassorelli et al, 2017; Cowan et al, 2019; Dave et al, 2019; 
Dale et al, 2020). 
 
 
2.10 Summary of the literature review 
Primary headaches are a thoroughly classified and a rather meticulously described 
set of disorders in neurology (Headache Classification Committee of the Inter-
national Headache Society, 1988, 2004, 2013 and 2018). The clear-cut diagnostic 
criteria for different entities create a reasonable basis for distinguishing separate 
diagnoses, in spite of sometimes being too mechanistic in clinical practice or 
epidemiological studies (Stovner et al, 2014). The methodology used in the 
earlier epidemiological research in primary headaches has been rather varied 
(Steiner et al, 2013) but since consensus guidelines on the principles of conduct 
of cross-sectional population-based studies of headache were published in 2014 
(Stovner et al, 2014), a shift towards a more standardized approach is evident. 
The epidemiological data on primary headaches are growing steadily worldwide. 
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In some regions, like Europe and North-America, multiple studies have been 
conducted, sometimes repeatedly in the same country, whereas in others, like 
Africa, South-America and Australia, the data are still largely missing. However, 
this information is crucial for the assessment of the disease burden and cost and 
for decision-making in public health in the society. The prevalence of primary 
headaches in Estonia has also not been studied before. The present study was 
designed to evaluate the prevalence of primary headaches in Estonia in order to 
gain data for further health policy planning. 
The fast digital evolution, like in almost all other aspects of life, has also been 
observable in the field of headache and headache epidemiology. Online approaches 
in headache studies have started to appear since the 2010s, most often looking 
into headache symptoms, associated factors, treatment practices or burden. 
Migraine is the most frequent primary headache studied via internet, followed by 
CH, and a few web-based surveys have been conducted on other primary head-
aches. However, large internet-based epidemiological studies that encompass all 
primary headaches and involve a population of a whole country have not been 
published before. Since traditional large population-based person-to-person 
epidemiological studies are resource and time consuming, web-based research 
could be a viable option in technologically highly developed countries. Estonia 
certainly qualifies as one, being one of the leading countries in the world 
regarding the usage of internet and web-based solutions per household (Inter-
national Telecommunication Union, 2017) and ranking high in the European 
Commission Digital Economy and Society Index (European Commission, 2019). 
To experimentally and evidentially address the question if web-based approach 
to the epidemiological studies of primary headache disorders could be useful and 
applicable, and what pitfalls there might be expected, an online headache 
questionnaire was developed and tested and a web-based survey on the preva-
lence of primary headaches was conducted. The results of the web-based survey 
were compared to the previously mentioned person-to-person population-based 
epidemiological study in Estonia to assess the differences and biases. 
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3. AIMS OF THE STUDY 
1.  To develop and test a questionnaire for headache epidemiological research in 
Estonia (Paper I) 
2.  To determine the one-year prevalence of primary headaches among 20–64-
year-old population in Estonia (Paper II) 
3.  To evaluate the applicability of web-based solutions in the epidemiological 
studies of primary headaches by comparing the results of a web-based survey 
to the population-based epidemiological study in Estonia (Paper III) 
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4. PARTICIPANTS AND METHODS 
This study was approved by the Research Ethics Committee of the University of 
Tartu (permissions no. 242T-11 and no. 252T-15). All the participants were 
informed of the purpose of the study and gave their written or digital informed 
consent for participation. 
 
 
4.1 Diagnostic questionnaire for headache  
epidemiological research in Estonia 
4.1.1 Questionnaire 
A headache questionnaire was composed in Estonian and named PRILEVEL 
(acronym from Estonian PRImaarsete peavalude LEVimus ja ELukvaliteet, “the 
prevalence and quality of life with primary headaches”) (Appendix A). It consisted 
of two parts. The first was designed to gather demographic data (age, weight, 
height, education, habitat (rural or urban)) and the possible headache risk-factors 
(physical activity, smoking, and coffee and alcohol consumption) of participants. 
The first part ended with the screening question about the presence of headaches: 
“During the last year have you had repeated headaches not caused by an acute 
infection, a medication’s side effects, medical procedures, or consumption of 
toxic substances including alcohol?” If the participant responded affirmatively, 
(s)he was introduced to the second, diagnostic part of the questionnaire. This was 
compiled of fourteen questions about different characteristics of headache 
(localisation, laterality, intensity, character, preceding/accompanying symptoms, 
frequency, duration, response to indomethacin, association with particular 
situations/activities, precipitating factors, drug consumption, and history of head 
trauma). A specifically designed digital algorithm provided a headache diagnosis 
based on the responses to the questions when possible. The algorithm strictly used 
the ICHD-3 beta criteria (Headache Classification Committee of the International 
Headache Society, 2013) to identify the following entities: episodic migraine 
with or without aura, chronic migraine, TTH (episodic or chronic), CH (episodic 
or chronic), paroxysmal hemicranias (episodic or chronic), short-lasting unilateral 
neuralgiform headache attacks (episodic or chronic), primary cough headache, 
primary headache associated with sexual activity, primary exercise headache, 
primary stabbing headache, cold-stimulus headache, nummular headache, hypnic 
headache, NDPH, headache attributed to trauma, trigeminal neuralgia or neuro-
pathy, and MOH. The algorithm always applied the ICHD-3 beta definite criteria 
for the diagnoses except for two aspects when diagnosing migraine. Firstly, the 
duration of an attack was allowed to last from four hours to seven days in order 
to not exclude participants who had attacks typical of migraine but who also had 
had status migrainosus. Secondly, the definite diagnostic criteria for migraine 
require the presence of at least one of the following – either nausea or vomiting 
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or photophobia and phonophobia (Headache Classification Committee of the 
International Headache Society, 2013). The algorithm made the diagnosis of 
migraine even if only photophobia or phonophobia alone was reported provided 
that the remaining criteria for migraine were fulfilled. 
The algorithm was not designed to identify primary thunderclap headache, 
because this entity requires a meticulous diagnostic workup to exclude secondary 
conditions. The diagnosis of external pressure headache was also omitted, because 
the exhaustive explanation of the nature, causes and precipitants of this type of 
headache was judged to be too tiring for the participant in comparison to its 
relatively small clinical importance. 
The algorithm was composed to make only a single diagnosis per each finished 
questionnaire except for the case when MOH would be identified. The diagnosis 
of MOH was additional to the primary (chronic) headache diagnosis. If the 
participant had more than a single type of headache, (s)he was asked to complete 
the questionnaire for each type of headache separately, thus avoiding overlooking 
any co-morbid headaches. 
The questionnaire was hosted by Tartu University Hospital’s patient website. 





All persons aged 18–65 who had been diagnosed with a definite headache 
disorder by a neurologist specializing in headaches at Tartu University Hospital’s 
Headache Clinic from February 2014 to March 2015 were invited to fulfil the 
questionnaire. They were informed of the questionnaire and the purpose of the 
study by phone. Consenting participants received an e-mail which included a link 
to the Tartu University Hospital’s patient website, a short introduction to the 
questionnaire, and guidelines for how to complete it. 
After answering the questions and before saving the data, patients were once 
more informed of the purpose of the study and also that by clicking the “Finished” 
button, they gave their informed consent to participate in the study. 
 
 
4.1.3 Statistical analysis 
The diagnoses made by the neurologists specializing in headaches were compared 
to the diagnoses made by the algorithm. Sensitivity, specificity, and (prevalence-
dependent) positive and negative predictive values of the algorithm were 
evaluated in the participant sample for each headache diagnosis (ICHD-3 beta 
second-digit-level diagnosis accuracy by the algorithm was required in order to 
count the diagnosis as correct) as well as for the larger groups of diagnoses in the 
study sample (in this case first-digit-level diagnosis accuracy was required to 
count the diagnosis as correct). After receiving the results of the statistical 
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analysis of the named parameters of the algorithm using ICHD-3 beta definite 
criteria, the same parameters were recalculated with added ICHD-3 beta probable 
diagnostic criteria for the most prevalent groups of diagnoses – namely migraine 
and tension-type headache. In this case first-digit-level diagnosis accuracy was 
required to count the diagnosis as correct. 
 
 
4.2 One-year prevalence of primary headaches in Estonia 
4.2.1 Participants 
The preselected sample of participants consisted of 3000 subjects aged 18–64 and 
was derived from Estonian National Registry. It was a random sample of 
inhabitants of Tartu city and Tartu county demographically representative of 





The survey was conducted from January 2016 to May 2017. The survey was 
conducted by telephone or face-to-face by fourteen trained medical students who 
used a structured questionnaire. If the participant could not be reached by phone 
on four different occasions, the interviewer visited his/her home address, and if 
the person was still not found, a note was left that contained a short introduction 




The questionnaire described previously under section 4.1.1 was used. The 
questionnaire was also translated into Russian using forward and backward 
translations to be used by native Russian speaking participants. If a respondent 




4.2.4 Caseness and headache diagnoses 
According to the data acquired from the questionnaire, the diagnosis of a 
headache disorder was made by a neurologist specializing in headaches applying 
the ICHD 3-beta criteria (Headache Classification Committee of the International 
Headache Society, 2013). 
The study was designed to evaluate the prevalences of the following entities: 
episodic and chronic migraine, episodic and chronic tension-type headache, 
chronic daily headaches (headache on more than 15 days a month), TACs and 
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other primary headaches except for primary thunderclap headache and external 
pressure headache. The latter two were omitted for reasons described under 
section 4.1.1. The headache had to fit either the definite or probable criteria of 
ICHD-3 beta to be considered as a case. The criteria were first applied for definite 
migraine, then definite tension-type headache, then probable migraine, then 
probable tension-type headache, then definite TACs or definite other primary 
headaches and finally probable TACs and probable other primary headaches. If a 
case did not fit under any entity as a probable or definite primary headache 
syndrome, it was labelled as unidentifiable. 
 
 
4.2.5 Statistical analysis 
The main outcome variables of the study were the one-year prevalences of 
primary headaches in Estonia. Data analysis was performed using R (R Core 
Team, 2018). For adjusting the study sample to match the population demo-
graphically weighting by age, gender, marital status, habitat and level of edu-
cation was implemented. Sample weights were calculated using ANES raking 
algorithm implemented in R package anesrake (Pasek, 2018). 
 
 
4.3 Applicability of web-based solutions  
in the epidemiological studies of primary headaches 
4.3.1 Survey and participants 
A web-based online survey was conducted in parallel to the survey described 
under sections 4.2.1–4.2.4 also from January 2016 to May 2017. 
The participants included in the online survey were Estonian citizens aged 20–
64 and they were recruited via internet. For this purpose, an online recruitment 
campaign was performed. Advertisements for the headache questionnaire 
described under section 4.1.1 were sent to different online portals and 150 000 e-
mails were sent to six most popular e-mail domains in Estonia. The portals and 
e-mail addresses were chosen by an advertisement company and were aimed at 
maximum coverage of Estonian digital community. The advertisements and e-
mails consisted of a short informative description of a health survey, avoiding 
any explanation that this was a headache survey in order to minimize participation 
bias. The advertisements and e-mails also contained a link to the headache 
questionnaire. The questionnaire was hosted by Tartu University Hospital’s 
server, which provides a highly secure mode for participants’ data storage. In 
order to reach the questionnaire, the participants had to log in with their unique 
personal Estonian ID cards so that double entries could be traced and managed 
appropriately. This also secured that only Estonian citizens of the appropriate age 
were included, since the ID card data include the date of birth of the participants. 
At the end of the questionnaire there was a more thorough description of the 
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purpose of the study explaining that it was a headache epidemiology study and 
making sure that participants, upon being fully informed, had the possibility of 
leaving the site without saving their data in case they decided not to give their 
consent. Otherwise, they saved their data by pushing the button „Finished“. 
In order to encourage participation a lottery was announced on the advertise-
ments and in the e-mails. The lottery draw was performed at the end of the study 
and two kinds of prizes were awarded to 11 random participants. The prizes were 




The questionnaire described previously under section 4.1.1 was used. In the 
online study, the questionnaire was self-administered similarly to the original 
validation process. The participants were required to complete all the questions 
both of the demographic and diagnostic parts in order to finish the questionnaire, 
thus avoiding missing data. 
 
 
4.3.3 Caseness and headache diagnoses 
After filling in the headache questionnaire, an ICHD-3 beta (Headache Classi-
fication Committee of the International Headache Society, 2013) based diag-
nostic algorithm was applied and the respondent received one of the following 
diagnoses: no headache, episodic or chronic migraine, episodic or chronic 
tension-type headache, one of trigeminal autonomic cephalalgias, one of other 
primary headaches except for primary thunderclap headache and external-
pressure headache, or, in case the described headache did not meet the criteria of 
any of the aforementioned entities, the unidentified headache was diagnosed. The 
headache had to fit either definite or probable criteria of ICHD-3 beta to be 
considered as a case (Headache Classification Committee of the International 
Headache Society, 2013). 
As multiple entries by single participants were expected, the following 
protocol was developed in order to manage these. In case the results of multiple 
questionnaire entries were identical, only the first entry was retained in the study. 
Thus, the multiple entries of the participants made by mistake or to enhance their 
chances of winning a prize by filling in the questionnaire several times were 
eliminated. If the results of the questionnaire did not overlap, the following 4 
options were possible. 
 
• Firstly, if the age reported by the participant did not match the age by ID 
(Estonian ID includes the date of birth) the entries were excluded as the 
participant was filling the questionnaire in under a false identity. 
• Secondly, if one entry resulted in a headache diagnosis and another in no 
headache, the “headache” entry was accepted and “no headache” entries were 
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excluded, because it is most probable that the “no headache” entries were 
completed in order to enhance the chances of winning the prize. 
• Thirdly, if different entries by a participant resulted in different headache 
diagnoses that did not exclude each other, they were all accepted as different 
headaches may occur in one person. 
• The fourth option was the case when different entries by a participant resulted 
in different headache diagnoses that excluded one another – for example the 
participant had both diagnoses of a chronic and an episodic form of the same 
headache, or both the probable and definite diagnoses of the same headache. 
In these cases, the chronic form was accepted and the episodic omitted, or the 
definite diagnosis accepted and the probable omitted, respectively. 
 
When multiple entries were included from the same participant, s/he was still 
counted as a single participant having multiple headache cases. In other words, 
the total number of participants in the sample did not increase, but the number of 
respective headache cases did. 
 
 
4.3.4 Statistical analysis 
The main outcomes of the online study were the one-year prevalences of primary 
headache disorders in the study sample. These prevalences were compared to the 
one-year prevalences of primary headaches in Estonian population acquired from 
the population-based person-to-person study described under section 4.2. 
Statistical methods used in both studies were identical. Data analysis was 
performed using R (R Core Team, 2019). Sample weights were calculated using 
ANES (American National Election Study (DeBell and Krosnick, 2009)) raking 
algorithm implemented in R package anesrake (Pasek, 2018) (a standard approach 
in situations where data need to be simultaneously weighted for multiple demo-
graphic criteria). Comparison of the sample proportions was conducted using 




5.1 Diagnostic questionnaire for headache  
epidemiological research in Estonia 
5.1.1 Enrolment of participants 
A total of five hundred and eleven headache patients from Tartu University Hos-
pital’s Headache Clinic were incorporated in the recruitment process, which started 
in January 2015 and ended in March 2015. One hundred and forty-five participants 
were included in final analysis, representing a response rate of 28% (Figure 1). 
 
 
Figure 1. Flowchart of the recruitment of the participants 
 































Included in the study
145 (28%)
 
Table 1. Demographic characteristics of the study participants  
Number of participants 145 
Age in years: mean  36,3 (24–72) 
Gender (% male) 17.2% 
Education:  
 Primary 2.1% 
 Secondary 36.6% 
 Vocational 14.5% 
 higher education 46.9% 
% living in urban area 77.2% 
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5.1.2 Testing and statistical analysis 
Having the headache specialist’s diagnosis as the gold standard, the sensitivity, 
specificity, positive and negative predictive values of the questionnaire and 
diagnostic algorithm using ICHD-3 beta definite criteria for each diagnosis were 
calculated. The respective results are depicted in Table 2. 
After additionally applying the ICHD-3 beta probable criteria, the specificity 
values did not decrease markedly but the sensitivity increased considerably for 
the most prevalent headache diagnosis groups – the sensitivity for all migraines 
increased from 0.56 to 0.80 and for all tension-type headaches from 0.52 to 0.60; 
the specificity values remained 0.90 and 0.92 respectively (Table 3). 
 
Table 2. Specificity, sensitivity, positive (PPV) and negative predictive values (NPV) of 
the questionnaire and diagnostic algorithm for the diagnoses in the study sample 
Diagnosis  Number 
of cases 
Specificity Sensitivity PPV NPV 
All migraines 108 0.97 0.56 0.78 0.91 
Episodic migraine without aura 74 0.95 0.57 0.48 0.96 
Episodic migraine with aura 18 0.99 0.28 0.69 0.96 
Chronic migraine 16 0.98 0.38 0.44 0.97 
All tension-type headaches 25 0.92 0.52 0.92 0.49 
Episodic tension type headache 19 0.93 0.53 0.92 0.54 
Chronic tension type headache 6 0.99 0.5 0.74 0.98 
Episodic cluster headache 2 1 0.5 1 1 
All other primary headaches 8 0.98 0.50 0.30 0.99 
Primary exercise headache 1 1 1 1 1 
Primary stabbing headache 2 1 0 NA 0.99 
Nummular headache 1 0.99 0 NA NA 
NDPH 4 0.99 0.5 0.08 1 
Headache attributed to head 
trauma 
6 0.99 0.5 0.62 0.99 
Medication overuse headache 18 1 1 1 1 
Trigeminal neuralgia 2 1 1 1 1 
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Table 3. Specificity, sensitivity, positive (PPV) and negative predictive values (NPV) of 
the questionnaire and diagnostic algorithm for the migraine and TTH diagnoses after 
incorporating the probable criteria 
Diagnosis Specificity Sensitivity PPV NPV 
All migraines 0.90 0.80 0.62 0.96 
All tension-type headaches 0.92 0.60 0.93 0.54 
 
 
5.2 One-year prevalence of primary headaches  
in Estonia 
5.2.1 Study sample composition 
Of the 3000 preselected participants 838 (27.9%) had insufficient contact data. 
Of the contactable sample of 2162 participants 919 (43.2%) refused and 1243 
(56.8%) consented to participate in the study. Of those 1243 consenting subjects 
28 had missing data or gave unusable answers, so the participating sample 
consisted of 1215 subjects (Figure 2). Hence, applying the recommendations for 
methodology of population surveys of headache prevalence from the Global 
Campaign against Headache (Stovner et al, 2014), the participation rate of our 
study was 56%. 
 
















Preselected sample from 
Estonian National Registry 
 N=3000 
Insufficient contact data 
N=838 






No headache 735 







(58.7% of the participating sample) 
Headache during previous year 
N=502 
(41.3% of the participating sample) 
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The demographic characteristics of the participating study sample were statisti-
cally significantly different from the overall Estonian population (Statistics 
Estonia, data from 01.01.2016, accessed 01.03.2018, (Table 4)). Compared to the 
general population, there were more women and more married people, the pro-
portion of subjects aged 30–49 years was higher, the level of education was 
higher and the proportion of people living in the rural areas was larger in the study 
sample. The study sample was adjusted to match the population demographically 
by weighting by age, gender, marital status, habitat and level of education. 
 
 
Table 4. Comparison of Estonian population and survey sample for distribution of 
gender, age, marital status, education and habitat 
 General population, 
20–64 years, 01.01.2016
Study sample p-value 
Gender, female (%) 50.4 56.5 
(95%CI 53.7–59.2) 
<0.001 
Age (%)   <0.001 
20–29 years 21.8 17.6  
30–39 years 23.1 25.7  
40–49 years 22.2 25.3  
50–59 years 22.1 20.9  
60–64 years 10.5 9.7  
Marital status (%)   <0.001 
Married 34.0 44.4 
(95%CI 42.0–47.5) 
 
Not married (incl. 
single, living with 
partner, divorced etc.) 
66.0 55.6  
Education (%)   <0.001 
primary or basic 12.5 6.0  
secondary or vocational 58.0 50.3  
higher 29.5 43.7  
Habitat (%)   <0.001 
urban 68.3 61.9  







5.2.2 One-year prevalence of primary headache disorders 
Of the participating 1215 respondents, 502 had had headache the previous year. 
The overall one-year weighted prevalence of headaches was 41% (Table 5). 
Initially, 34 participants (6.8% out of 502) reported more than one type of 
headache, and after the final diagnosis was made by a neurologist, it turned out 
that more than half of them had been describing the same type of headache as two 
different ones. Thus, only 16 (3.2%) of the participants had reported more than 
one type of headache. 
 
Table 5. Weighted one-year prevalences of primary headaches in Estonia (weighted by 
age, gender, marital status, habitat and education) 
PRIMARY  
HEADACHES 








with 95% CIs 
All headache 518 497.8 41.0 (38.2–43.8) 
All migraine 233 215.6 17.7 (15.7–20.0) 
• Episodic migraine 221 204.6 16.8 (14.8–19.1) 
Definite 93 80.1 6.6 (5.3–8.2) 
Probable 128 124.5 10.2 (8.6–12.1) 
• Chronic migraine 12 11.0 0.9 (0.5–1.7) 
Definite 9 8.8 0.7 (0.4–1.4) 
Probable 3 2.2 0.2 (<0.1–0.7) 
All tension-type headache 228 218.7 18.0 (15.9–20.3) 
• Episodic TTH 213 200.0 16.5 (14.4–18.7) 
Definite 154 143.3 11.8 (10.1–13.8) 
Probable 59 56.7  4.7 (3.6–6.0) 
• Chronic TTH 15 18.7 1.5 (1.0–2.5) 
Definite 14 18.1 1.5 (0.9–2.4) 
Probable 1 0.6 0.1 (<0.001–0.5) 
TACs 3 4.5 0.4 (0.1–1.0) 
Other primary headaches 27 29.8 2.5 (1.7–3.5) 
Chronic daily headache 
(headache >15 days a month) 
30 32.2 2.7 (1.9–3.8) 





Migraine was reported by 233 respondents and TTH by 228 respondents, and the 
weighted one-year prevalences were 17.7% and 18.0% respectively. Definite 
episodic migraine was diagnosed in 93 (weighted one-year prevalence of 6.6%) 
and probable episodic migraine in 128 respondents (weighted one-year pre-
valence of 10.2%). Twelve respondents reported having a headache that fulfilled 
the criteria for chronic migraine (weighted one-year prevalence 0.9%). Definite 
episodic TTH was diagnosed in 154 (11.8%) and probable episodic TTH was 
diagnosed in 60 (4.7%) respondents. Chronic TTH was reported by 15 partici-
pants (1.5%). Distribution of all migraine and all TTH by age and gender are 




Figure 3. Distribution of all migraine 
by age and gender 
Figure 4. Distribution of all TTH by 
age and gender 
TACs were found in 3 participants, so the weighted one-year prevalence was 
0.4% (Table 5). All other primary headaches were reported by 27 participants, 
having a weighted one-year prevalence of 2.5% (Tables 5 and 6). Chronic daily 
headache was found in 30 participants (weighted one-year prevalence of 2.7%). 
This group includes participants with chronic migraine, chronic tension-type 
headache (Table 5) and the cases that fulfilled the criteria for NDPH (Table 6). 






Table 6. Weighted one-year prevalences of identified other primary headaches in Estonia 
(weighted by age, gender, marital status, habitat and education) 









Primary cough headache 1 0.6 0.1 
Primary exercise headache 9 12.2 1.0 
Probable primary exercise 
headache 
1 1.1 0.1 
Primary headache associated 
with sexual activity 
1 1.0 0.1 
Cold-stimulus headache 1 0.9 0.1 
Primary stabbing headache 3 3.1 0.3 
Nummular headache 4 4.5 0.4 
Hypnic headache 1 1.0 0.1 
Probable hypnic headache 3 2.9 0.2 
NDPH 3 2.5 0.2 
 
 
5.3 Applicability of web-based solutions in the 
epidemiological studies of primary headaches 
5.3.1 Online study sample composition 
During the period from January 2016 to May 2017, five thousand seven hundred 
and eight entries were made by 5347 individual participants to the online 
headache questionnaire. Five thousand and thirty-two participants filled in the 
questionnaire only once, 250 participants made multiple entries, which resulted 
in identical diagnoses, and 65 participants made multiple entries with differing 
diagnoses. After addressing the multiple entries according to the protocol 
described under section 4.3.3, 5363 entries were included and 340 entries were 
excluded from the final analysis. Of the 5347 participants 3896 (72.9%) had no 
headache, 1436 (26.8%) had only one type of headache and 15 (0.3%) had more 
than one type of headache (Figure 5). 
The demographic data of the study sample are depicted in Table 7 alongside 
the data for Estonian population (Statistics Estonia, data from 01.01.2016, 
accessed 01.03.2018). 
The online study sample demographics were statistically significantly different 
from Estonian population. The proportion of women was higher, participants 
were younger, there were more married people, the level of education and the 
proportion of people living in urban areas were higher in the online study sample 
compared to the general population. Hence, the study sample was adjusted to 
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match the population demographically by weighting by age, gender, marital 




Figure 5. Study sample composition 





Table 7. Comparison of Estonian population and online study sample 
 General population, 
20–64 years, 01.01.2016
Study sample p-value 
Gender, female (%) 50.4 71.5 
(95% CI 70.3–72.1)
<0.001 
Age (%)   <0.001 
20–29 years 21.8 24.7  
30–39 years 23.1 31.0  
40–49 years 22.2 24.1  
50–59 years 22.1 15.4  
60–64 years 10.5 4.7  
Marital status (%)   <0.001 
Married 34.0 36.5 
(95% CI 35.2–37.8)
 
Not married (incl. 
single, living with 
partner, divorced 
etc.) 
66.0 63.5  
Education (%)   <0.001 
primary or basic 12.5 3.0  
secondary or 
vocational 
58.0 37.4  
higher 29.5 59.6  
Habitat (%)   <0.001 
urban 68.3 71.3  
rural 31.7 28.7  
 
 
5.3.2 One-year prevalences of primary headache disorders  
in the online study sample. 
The adjusted prevalences of primary headaches in the online study sample 









Table 8. Weighted one-year prevalences of primary headaches in the online study sample 
PRIMARY  
HEADACHES 








with 95% CIs 
All headache 1467 1234.7 23.1 (22.0–24.3) 
All migraine 508 404.1 7.6 (6.9–8.3) 
• Episodic migraine 480 375.6 7.0 (6.4–7.8) 
Definite  198 159.6 3.0 (2.6–3.5) 
Probable  282 216.0 4.0 (3.5–4.6) 
• Chronic migraine 28 28.5 0.5 (0.4–0.8) 
Definite  12 12.7 0.2 (0.1–0.4) 
Probable  16 15.8 0.3 (0.2–0.5) 
All TTH 829 703.3 13.2 (12.3–14.1) 
• Episodic TTH 781 654.9 12.2 (11.4–13.2) 
Definite  558 456.1 8.5 (7.8–9.3) 
Probable  223 198.8 3.7 (3.2–4.3) 
• Chronic TTH 48 48.4 0.9 (0.7–1.2) 
Definite  33 30.2 0.6 (0.4–0.8) 
Probable  15 18.2 0.3 (0.2–0.5) 
TACs 2 5.3 0.1 (0.0004–0.2) 
Other primary headaches 55 57.1 1.1 (0.8–1.4) 
Chronic daily headache 
(headache >15 days a month) 
76 76.9 1.4 (1.1–1.8) 
Unidentifiable 43 41.8 0.8 (0.6–1.1) 
 
5.3.3 Comparison of the headache prevalences  
in the person-to-person vs online study samples 
The comparison between the adjusted prevalences of primary headaches in 
Estonian population-based person-to-person study sample described under 
section 5.2 and in the online study sample (weighted by age, gender, marital 








Table 9. Comparison of weighted one-year prevalences of primary headaches in the 




prevalences (%) with 95% 




with 95% CIs in the 
online study sample 
All headache 41.0 (38.2–43.8) 23.1 (22.0–24.3) 
All migraine 17.7 (15.7–20.0) 7.6 (6.9–8.3) 
• Episodic migraine 16.8 (14.8–19.1) 7.0 (6.4–7.8) 
Definite 6.6 (5.3–8.2) 3.0 (2.6–3.5) 
Probable 10.2 (8.6–12.1) 4.0 (3.5–4.6) 
• Chronic migraine 0.9 (0.5–1.7) 0.5 (0.4–0.8) 
Definite 0.7 (0.4–1.4) 0.2 (0.1–0.4) 
Probable 0.2 (<0.1–0.7) 0.3 (0.2–0.5) 
All TTH 18.0 (15.9–20.3) 13.2 (12.3–14.1) 
• Episodic TTH 16.5 (14.4–18.7) 12.2 (11.4–13.2) 
Definite 11.8 (10.1–13.8) 8.5 (7.8–9.3) 
Probable 4.7 (3.6–6.0) 3.7 (3.2–4.3) 
• Chronic TTH 1.5 (1.0–2.5) 0.9 (0.7–1.2) 
Definite 1.5 (0.9–2.4) 0.6 (0.4–0.8) 
Probable 0.1 (<0.001–0.5) 0.3 (0.2–0.5) 
TACs 0.4 (0.1–1.0) 0.1 (0.0004–0.2) 
Other primary headaches 2.5 (1.7–3.5) 1.1 (0.8–1.4) 
Chronic daily headache 
(headache >15 days a month) 
2.7 (1.9–3.8) 1.4 (1.1–1.8) 
Unidentifiable 2.0 (1.3–3.0) 0.8 (0.6–1.1) 
 
The percentage of headache sufferers in general was considerably smaller in the 
online study sample. However, among the participants who had headaches, the 
proportions of different headache diagnoses were similar in the two studies (Table 
10 and Figure 6) with only the proportions of episodic migraine and episodic 
tension-type headache being statistically different. There were proportionally less 
migraine and more tension-type headache sufferers in the online study sample 






Table 10. Comparison of proportions of different primary headache diagnoses among 















































Episodic migraine 204.6 42 375.6 31 < 0.001 
Chronic migraine 11 2 28.5 2 1 
Episodic TTH 200 41 654.9 54 < 0.001 
Chronic TTH 18.7 4 48.4 4 0.96 
TACs 4.5 1 5.3 1 0.41 
Other primary 
headaches 
29.8 6 57.1 5 0.31 
Unidentifiable 24 5 41.8 3 0.21 
 
 
Figure 6. Proportions of different primary headache diagnoses among headache sufferers 
in the person-to-person and online study samples 
Ep M: episodic migraine; Chr M: chronic migraine; Ep TTH: episodic tension type headache; Chr 































6.1 Diagnostic questionnaire for headache  
epidemiological research in Estonia 
The main objective of the first part of the study (paper I) was to test the developed 
online questionnaire with its digital algorithm described in sections 4.1 and 5.1 
before using it in further epidemiological research. 
The main reason the headache questionnaire was originally composed as an 
online version was the hypothesis that implementing web-based solutions could 
potentially provide opportunities for gaining data representative of a general 
population in a more time and resource efficient manner than the traditional 
person-to-person epidemiological studies in headache prevalence. It must be 
acknowledged that such an approach is reasonable only within an appropriate 
setting like Estonia, where the availability of online solutions and their real 
utilization is sufficiently high and has already become a natural part of everyday 
life in the country (International Telecommunication Union, 2017; European 
Commission, 2019) and the extensive majority of the general population 
(especially those under investigation – that is, 18–64-year-olds) are actively and 
comfortably in touch with e-solutions on an everyday basis. 
The questionnaire and the diagnostic algorithm applied (at the time of the first 
part of the study) the latest ICHD-3 beta criteria to diagnose a wide spectrum of 
headache disorders – including virtually all the primary headache disorders 
except for primary thunderclap headache and external pressure headache, which 
is rather a rare case in headache epidemiological studies published to the date. 
Another strength of the questionnaire is that it is fairly simple and easy to 
complete. This is supported by the finding that only about 4% of the participants 
filled the questionnaire in incorrectly, either by giving illogical responses or by 
not answering all the compulsory questions. One more advantage of the online 
questionnaire is that since digital identification is required of the participant, it 
enables the collection of personalized data, which in turn permits the elimination 
of repeated data entries and the acquisition of accurate prevalence estimates of 
primary headache disorders. 
The quality control of the referent headache cases of the first study was very 
good as all participants were previously consulted and diagnosed with a headache 
disorder by a Tartu University Hospital’s Headache Clinic specialist. 
The diagnostic algorithm was at first designed to apply strictly the ICHD-3 
beta definite criteria – this is why the questionnaire initially had very high 
specificities. Sensitivities for some of the headache diagnoses in the study 
sample, however, turned out to be low. This especially relates to the sensitivities 
for episodic migraine with aura, chronic migraine, primary stabbing headache, 
and nummular headache. One of the reasons the algorithm could not detect the 
diagnosis in the case of migraines was related to the participants reporting their 
headache duration without treatment to be less than four hours, which automati-
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cally excluded the definite migraine diagnosis, according to ICHD-3 beta. In 
some cases, the migraine diagnosis was not identified, because the participants 
did not report any accompanying symptoms, although these were clearly stated 
in their headache specialist medical history. In some instances, the algorithm did 
not recognise a definite diagnosis, because the case itself was atypical and thus 
undetectable by the strict criteria, although the physician’s diagnosis was 
established as a definite primary headache. Excluding the previously mentioned 
values, the sensitivities for other diagnoses were 0.5 or above. Similar sensitivity 
values (53.8–57.2%) were also achieved by Wilbrink et al for the LUCA and 
QATCH online questionnaires (Wilbrink et al, 2013). The authors concluded that 
such an approach is acceptably accurate and reliable for a certain part of 
epidemiological studies with specific purposes. However, this is not the case in 
population-based epidemiological studies. In addition, another aspect has to be 
taken into account when interpreting the calculated sensitivity values. The present 
statistical methodology for calculating sensitivity values requires an exact 
knowledge of the prevalence rates of the disorder(s) in the particular settings where 
the study is being performed. Since no such data for Estonia were available, the 
prevalence rates needed for the analysis were adopted from studies performed 
elsewhere. The latter ones, however, may vary to a considerable extent depending 
on the specific headache disorder (Stovner et al, 2006; Stovner et al, 2007, 
Stovner and Andree, 2010). Hence, based solely on the adopted prevalence rates, 
the real sensitivity values might be somewhat different from the presented ones. 
As applying only definite ICHD-3 beta criteria for different headache dis-
orders resulted in unacceptably low sensitivity estimates, the ICHD-3 beta criteria 
for probable diagnoses were also incorporated in the algorithm. This increased 
sensitivity considerably (for example, in the case of migraine, from 0.56 to 0.80) 
by detecting those cases that did not fulfil the definite diagnostic criteria but in 
real life lead to the clinical diagnosis by the physician. Including criteria for prob-
able headache diagnoses helps to address another important aspect in headache 
epidemiological studies – it minimizes the influence of recall bias (patients 
forgetting to report one or several headache characteristics) on the results, which 
in turn brings the prevalence rates closer to real ones. Based on these findings, it 
can be suggested that strictly applying the ICHD-3 beta definite criteria within 
the epidemiologic studies can lead to an underestimation of true prevalence 
values of primary headache disorders. This is in concordance with findings from 
earlier studies (Lanteri-Minet et al, 2005; Stovner and Andree, 2010). 
Limitations of the study testing the online questionnaire must be mentioned. 
The response rate of the study is not high (28%). However, it is considered 
acceptable. For example, when validating the QATCH online questionnaire, 
Wilbrink et al had the same variable at 20% (Wilbrink et al, 2013). A rather low 
response rate also contributed to the study sample being relatively small and all 
the diagnoses that the algorithm was designed for not being covered. For instance, 
no participants with rather rare headache disorders such as chronic CH, par-
oxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks, 
primary cough headache, primary headache associated with sexual activity, cold-
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stimulus headache, or hypnic headache could be enrolled. For some entities, 
namely episodic CH, primary exercise headache, nummular headache, primary 
stabbing headache, and trigeminal neuralgia, there were only a few participants, 
so the conclusiveness for these diagnoses is not strong. This is also why the 
sensitivities for nummular headache and primary stabbing headache were very 
low. 
Secondly, it must be acknowledged that the sensitivities and specificities have 
been calculated on a sample of “pre-educated” patients, as they had been to a 
headache specialist consultation previously. This can be an important source of 
information bias, since pre-educated participants are more likely to recognise the 
different aspects (like the presence or lack of accompanying symptoms or duration 
of the episodes) of their headaches. Thus, the sensitivities and specificities of the 
questionnaire and the acquired prevalence rates of different headache disorders 
may decrease in case the questionnaire is applied to the general population, 
leading to possible underestimation of headache prevalence. 
In conclusion, the online questionnaire, especially after adding the ICHD-3 
beta criteria for probable headache diagnoses to the diagnostic algorithm, had 
acceptably high specificity and sensitivity for the main entities in headache 
epidemiology – namely migraine and TTH, to be applied in the further study. 
 
 
6.2 One-year prevalence of primary headaches in Estonia 
The aim of the second part of the study (paper II) was to estimate the one-year 
prevalences of primary headache disorders in adult population in Estonia. This 
was the first headache prevalence study conducted in this country. 
The general one-year prevalence of headache in Estonia (41%) is somewhat 
lower than the mean prevalence in Europe (53%) (Stovner and Andree, 2010). It 
is comparable to the headache prevalences reported in Georgia (Katsarava et al, 
2009) and Italy (D’Alessandro et al, 1988) and higher than the prevalences in 
Sweden (Molarius et al, 2006), Greece (Mitsikostas et al, 1996) and France 
(Henry et al, 2002). 
The one-year prevalence of both probable and definite episodic migraine 
combined in Estonia (16.8%) is comparable to the mean prevalence of migraine 
in Europe (14.7%) (Stovner and Andree, 2010), being closest to the respective 
one-year prevalences in France (Henry et al, 2002), Croatia (Zivadinov et al, 
2001), the Netherlands (Launer et al, 1999), Georgia (Katsarava et al, 2009) and 
Moldova (Moldovanu et al, 2007). 
There are extreme variations in the prevalences of episodic TTH across 
regions and cultures worldwide (Stovner et al, 2007; Sahler, 2012). The estimated 
one-year prevalence of episodic TTH in Estonia (16.5%) appears to be about three 
times lower than the mean prevalence in Europe (62.6%) (Stovner and Andree, 
2010). The variation of the prevalence of TTH within Europe itself is wide too – 
ranging from 18% in Moldova (Moldovanu et al, 2007) to 86.5% in Denmark 
(Lyngberg et al, 2005). The differences in methodological approaches across 
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studies, diagnostic overlap with probable migraine, variability in headache 
awareness and socioeconomic situation across countries or unknown genetic or 
environmental factors are the suspected reasons behind this phenomenon (Steiner 
et al, 2013; Stovner et al, 2014; Sahler, 2012). The low one-year prevalence rate 
of episodic TTH in this study could be due to two types of factors – sociocultural 
and methodological. Firstly, in Estonia it is not customary to complain about 
milder pain or headaches nor to consider them as diseases or noteworthy health 
issues, thus the infrequent or subtler forms of TTH might not be paid attention to 
and go unreported. Additionally, in case of milder headaches as TTH generally 
are, there is always the problem of recall bias and thus infrequent faint headaches 
might simply not be remembered over the period of a year. 
Secondly, there is a set of possible methodological reasons for this low 
prevalence of episodic TTH in this study. As described under section 4.2.4 
previously, both definite and probable categories for both migraine and TTH were 
included. If a case fulfilled both criteria for migraine and TTH the first was 
favoured over the latter. This means that in cases of doubt the prevalence of TTH 
could be slightly underestimated in favour of the prevalence of migraine. Another 
methodological aspect, which is generally accepted as a large problem in 
epidemiological studies, is the occurrence of multiple headache types in the same 
subject (Stovner et al, 2014). The respondents tend to report the most bothersome 
headache, despite of being offered the opportunity to describe more than one. 
Thus, respondents who have comorbid migraine with TTH, might report the 
former and omit the latter. This is also supported by the data from this study, 
since the proportion of participants reporting more than one type of headache was 
small (6.8%) and the real comorbidity after the cases had been diagnosed was 
even two times smaller. As under-reporting is not the case in clinical experience, 
it again points to the possibility of underestimation of milder comorbid headache 
disorders, most prominently infrequent episodic TTH. Similar problems with 
underestimating the prevalence of episodic TTH in case of comorbid migraine 
has been reported before (Zwart et al, 2004). Lastly, one of the possible 
methodological reasons for underestimating the prevalence of episodic TTH is 
due to the limitations related to the screening question used in this study, which 
will be discussed further on in this section. 
Aside from the episodic TTH, the prevalence of chronic TTH in this study 
(1.5%) is comparable to that of Europe (3.3%) (Stovner et al, 2010), being the 
closest to Denmark (0.9%) (Russell et al, 2006) and Germany (1.3%) (Pfaffenrath 
et al, 2009). 
The mean one-year prevalence of CDH (headache on ≥ than 15 days per 
month) has been reported to be around 4% in Europe (Stovner et al, 2010), 
however, the prevalences vary across regions being somewhat lower in Western 
Europe (Rasmussen et al, 1991; Henry et al, 2002; Wiendels et al, 2006; Grande 
et al, 2008) and higher in Eastern Europe (Lyngberg et al, 2005; Katsarava et al, 
2009; Rastenytė et al, 2017). The finding of the one-year prevalence of CDH of 
2.7% in this study is closer to the Western European prevalence. 
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TACs are rare and therefore it is impossible to validate a questionnaire with 
sufficient power to make a reliable diagnosis by that alone. However, there were 
three cases in this study sample in which the reported headaches fulfilled the 
definite or probable criteria for TACs, corresponding to the one-year prevalence 
of 0.4%, which is comparable to the previous studies on the prevalence of CH in 
European countries (Sjaastad and Bakketeig, 2003; Torelli et al, 2005; Ekbom et 
al, 2006; Katsarava et al, 2007 and 2009; Stovner et al, 2010). 
The same problem of rarity and lack of a reliably validated questionnaire 
exists when it comes to other primary headaches. Data on the prevalences of these 
entities is even scarcer. The Bruneck Study from Northern Italy estimated the 
one-year prevalence of all other primary headaches combined to be 1.7% 
(Schwaiger et al, 2009). This is comparable to our finding – 2.5% of our 
participants reported different headaches, which did not fulfil ICHD 3-beta 
criteria for neither migraine nor TTH but did so for either definite or probable 
criteria for the entities described in section 4 of the ICHD 3-beta. 
A slight proportion of the differences in the prevalences found in this study as 
compared to the previous headache studies could have occurred due to the fact 
that the ICHD 3-beta criteria were used to diagnose the cases whereas the 
previous studies used the ICHD 2. 
This person-to-person prevalence study has several limitations. Firstly, the 
participation rate of the study was 56%. This is a moderate response rate (Stovner 
et al, 2014). It can be speculated that in addition to Estonian people being rather 
reserved and conservative when it comes to communication on health-related 
topics, one of the reasons for refusing to participate in the study is the limited 
knowledge about headaches and their impact in the general population. Hence, 
the problem is underappreciated, and people are not motivated enough to 
participate in such a study. Another reason for refusal to participate particularly 
over the phone may be the negative influence of advertisement by phone, which 
is rather prevalent in Estonia. It is thus possible that people are put off by surveys 
that are carried out over the telephone. Quite a large proportion of the preselected 
sample (27.9%) could not be reached because of insufficient contact data. It could 
partly be due to the fact that the Estonian National Registry was last updated in 
2011 when the latest census was conducted, while this survey started in 2016. 
This leaves a time gap of five years during which a proportion of contact data had 
inevitably expired. It is also possible that of the 838 people whom were con-
sidered as having insufficient contact data, a number would actually have 
qualified as non-responders either because they did not want to answer a phone 
call from an unknown number, or because they chose not to contact the study 
team after they received the note that was left to their home address by one of the 
investigators. The size of the proportion of these subjects is impossible to 
determine retrospectively and it is a possible source of selection bias. It must also 
be taken into account that people with headache are more willing to participate 
in a headache study. Given that 43.2% of the contactable sample refused to 
participate in the study, a possible interest bias that may lead to an overestimation 
of the true prevalence of headache disorders can not be totally excluded. 
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Secondly, a possible source of bias was created by using a questionnaire that 
was validated in a clinical setting as discussed previously under section 6.1. This 
again created the risk of underestimating the true prevalences in the population, 
since headache clinic patients are pre-educated and know how to answer the 
questions more precisely. In order to compensate for these differences between 
the validation sample and the general population, the interviews were carried out 
by medical students so the participant could ask for clarification if in doubt or 
confused about the questions asked. Thus, although during the aforementioned 
validation study the questionnaire was self-administered and in the population-
based epidemiological study the questionnaire was administered by telephone or 
face-to-face by medical students, this would not lead to significant over- or 
underestimation, because person-to-person interview gives the participant the 
possibility to ask specifying questions in case of doubt resulting in more reliable 
responses than with a self-administered questionnaire. 
Lastly, one source of possible underestimation of the prevalences can be 
hidden within the screening question. The specific wording was used to avoid 
contamination of the data by secondary headaches, however, it has been shown 
that such a non-neutral screening question may produce false negatives (Stovner 
et al, 2014). As mentioned before in this section, this can also be one of the 
reasons why the prevalence of episodic TTH in our study was lower than in other 
countries nearby. The subjects were asked if they had had „recurrent“ headaches, 
and it may be suspected that people with infrequent and milder headaches do not 
consider these attacks as recurrent and thus do not report them. This may cause 
the underestimation of all types of headaches, but most of all episodic TTH, 
which is by definition a milder and less bothersome headache (Zwart et al, 2004). 
The main strength of this population-based person-to-person study is that it 
estimated the one-year prevalence of almost all primary headaches in Estonia, 
including migraine and TTH as the socioeconomically most bothersome entities 
as well as the rare TACs and other primary headaches. While the previously 
discussed uncertainties cannot be denied in the estimates, the results of this study 
may be considered as representative of Estonian population aged 18–64 years. 
The results are comparable to previous findings in other European countries, 
except for the episodic TTH. Another strength of the study is the low proportion 
of unidentified headaches (2%) in the sample. Lastly, the most up-to-date 
classification for headache case ascertainment was used, while the vast majority 
of prevalence studies published in recent years were based on the previous – 








6.3 Applicability of web-based solutions in the 
epidemiological studies of primary headaches 
The third part of the study was aimed to experimentally and evidentially address 
the question if web-based approach to the epidemiological studies of primary 
headache disorders could be useful, and what pitfalls there might be expected. 
The comparison between the online and person-to-person survey methods would 
be optimal, the most correct and informative only if both surveys were performed 
within the same population during the same time period. This was the case here, 
as the online study described under sections 4.3 and 5.3 was compared to the 
person-to-person study described under sections 4.2 and 5.2. Online solutions 
have been used in headache research previously (see section 2.9) but there have 
been no attempts to conduct an online survey for all primary headache epidemio-
logy involving a whole country. 
One of the considerations in favour of online approach to epidemiological 
studies is time. Although the online headache questionnaire was available for 
fifteen months, it could be noticed that most of the entries were made in close 
temporal connection to the launches of the online advertisement and e-mail 
campaigns with most of the entries (n=4082, 76% of total) made during 3 months’ 
time after the release of the campaign. This means that compared to the traditional 
methods of epidemiological studies it presents a much faster and cost-effective 
means of data collection. Additionally, the online study sample was considerably 
larger than the sample obtained in the offline person-to-person study that was 
carried out in parallel. Hence the power of the study is also bigger and statistical 
corrections can be made with smaller error. This is one of the biggest benefits of 
online surveys – the acquisition of large samples with less consumption of time 
and resource. 
The prevalence of all headache in the online study sample after adjusting it to 
the general population by age, gender, marital status, habitat and education was 
only 23.5% – almost 2 times smaller than the prevalence of all headache in the 
population-based random sample person-to-person survey performed in parallel. 
This is likely to mean that the online survey was significantly biased towards the 
people without headache. We speculate that one of the reasons this could have 
occurred was the selection bias created by the lottery that was originally intended 
to enhance participation. Since the potential reward was a gym membership, it is 
possible that physically more active individuals may have been more likely to 
participate, reducing the prevalence of headaches (Amin et al, 2018). It is also 
possible that a proportion of the participants did not take the trouble to fill in the 
questionnaire truthfully even if they had had a headache during the previous year 
and simply took the easy way out by saying they had not in order to be able to 
participate in the aforementioned lottery. Although participants not admitting to 
having had a headache could not be totally excluded in the person-to-person 
survey, it is definitely more likely to have occurred in the web-based approach. 
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When omitting the participants without headache and looking at the pro-
portions of primary headache diagnoses among those who reported headache in 
the online study, they are surprisingly similar to those found in the population 
based person-to-person random sample survey in Estonia (Figure 6, Table 10). 
The only statistically different proportions were those of episodic migraine and 
episodic TTH, whereas the proportions of chronic migraine, chronic TTH, TACs, 
other primary headaches and even unidentified headaches were almost identical. 
Furthermore, even the proportions of the statistically different episodic TTH and 
episodic migraine are still similar to the proportions of their counterparts in the 
population-based person-to-person random sample study in the respect that these 
are still the largest and most prevalent diagnoses of primary headaches in the 
samples: in both studies, episodic TTH and episodic migraine together comprise 
83% and 85% of the primary headaches, respectively. The proportion of episodic 
TTH is larger and the proportion of episodic migraine is equally smaller in the 
online study compared to the person-to-person study. One of the reasons for this 
discrepancy might be the fact that in the population-based person-to-person study 
the questionnaire was administered face-to-face or by telephone interviews 
whereas in the online study the questionnaire was completely self-administered. 
Since migraine diagnosis requires more detail (presence of accompanying 
symptoms etc) these nuances might be missed when the questionnaire is self-
administered as opposed to the situation where the participant can ask clari-
fications from the interviewer. On the other hand, most of the headache preva-
lence studies so far have demonstrated that TTH usually is more prevalent than 
migraine in any given population (Stovner et al, 2007; Stovner and Andree, 
2010). As described previously, the prevalence of episodic TTH in the popu-
lation-based person-to-person random sample study (18%) is exceptionally low 
when compared to other countries in the same North-Eastern European region. 
The reasons for this possible underestimation were also discussed in the previous 
section. However, this raises the question of whether the online study could have 
reflected the proportions of primary headache disorders in the population even 
more truthfully. Nevertheless, it is apparent that underestimation of headache 
prevalence would be one of the most troubling issues of online prevalence studies. 
Another important factor, that the third part of the study underlined, is the 
necessity of having the participants identify themselves by some unique ID 
method. The 671 multiple entries by the same participants in the online study 
(about 12% of all the entries) certainly point to the fact that in such web-based 
surveys it is vital to have an identification method that would grant the means to 
manage the situation, especially where multiple entries increase the chances of 
winning a prize for participants. This again provides evidence that if lotteries and 
other similar “stimulating packages” are to be used to boost participation, it must 
be applied with utmost care to minimize the inevitable bias. 
The main limitations of the online study are related to the sampling methods. 
Valid conclusions of the population of interest (in this case Estonian population 
of 20–64 years of age) require probability sampling, where all members of the 
population have an initial probability of being selected to the study sample 
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(Stovner et al, 2014). In our case it means that since almost about 87% of 16–74-
year-olds in Estonia use internet on daily basis (International Telecommunication 
Union, 2017), about 13% of the population would be isolated from the possibility 
of being invited to a study when conducted online. However, there is no infor-
mation about the age distribution of the non-users within this 13%. It is highly 
probable that most non-users are in the older age group. Since the online study 
sample’s upper age limit was 64 years, it is quite possible that the actual 
percentage of internet users within the targeted age-population is even higher than 
87%, but this remains speculative due to lack of respective data. 
The hypothesis that high internet coverage among the general population in 
Estonia would be a factor sufficient enough for obtaining a representative sample 
by the chosen method of access and engagement was tested. The analysis of the 
demographic data of the sample evidentially overruled this hypothesis. The 
sample of 5347 participants was statistically significantly different form the general 
population of Estonia – it consisted of a younger, more educated and more urban 
group of people and there were more women than men among the participants. 
The smallest difference, although statistically significant, was in the marital status 
of the participants compared to the general population – there were more married 
people in the study sample. This shows that simply by addressing the digital 
community based on the most popular sites and domains does not grant a 
representative sample of general population even in the countries with highly 
developed information technology and in order to obtain representative samples 
in the future online epidemiological studies the methods of sampling, access and 
engagement must still be more conservative (Stovner et al, 2014). There can be 
several possible solutions: the targeted invitation to the study could be linked to 
banking systems, e-health registries or e-mail addresses from national population 
registries in countries that use corresponding solutions extensively among adult 
population. 
The evidence provided by the comparison of the online and person-to-person 
studies should be considered when planning further research and generating 
guidelines for using web-based approaches in headache epidemiology.  
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7. CONCLUSIONS 
1. The developed and tested online headache questionnaire had reasonably high 
specificity and sensitivity for the main entities in headache epidemiology – 
namely migraine and TTH, to be acceptable for using the tool in an epidemio-
logical study. Strictly applying the ICHD-3 beta definite criteria within the 
epidemiologic studies lead to an underestimation of true prevalence values of 
primary headache disorders, and probable criteria should be included to 
increase the sensitivity of questionnaires. 
 
2. The one-year prevalences of primary headache disorders in Estonia are 
comparable to previous findings in other European countries, except for the 
episodic TTH. The low prevalence of episodic TTH is most probably an 
underestimation due to limitations of the study. The findings of the study mean 
that, like in other countries, primary headaches in Estonia are an important 
cause of morbidity, loss of quality of life and personal suffering as well as a 
prominent socioeconomic burden. 
 
3. In the face of an already extensive and rapidly increasing usage of internet and 
IT-solutions among the general population, online headache epidemiology 
research could be a time- and resource efficient alternative in technologically 
developed countries. In addition to the possibility of obtaining larger study 
samples in relatively short time periods, the IT solutions are capable of 
providing participant identification methods that enable avoiding data con-
tamination and are able to distinguish the proportions of most primary head-
ache disorders among the headache sufferers. However, further research is 
needed to find more reliable methods of online access and engagement to gain 
representative samples and overcome the pitfalls of bias and most probably 
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9. SUMMARY IN ESTONIAN 
Esmaste peavalude levimus Eestis ning internetipõhise lahenduse 
kohaldatavus peavalude epidemioloogia alases uurimistöös 
Esmased peavalud on iseseisvad haigused, millel on erinevad, kuigi mitte lõpuni 
teadaolevad patofüsioloogilised mehhanismid, ning mida ei põhjusta mingi muu 
haigus või tervisehäire. Esmaste peavalude hulka kuuluvad migreen, pingetüüpi 
peavalu, trigeminaalautonoomsed tsefalalgiad ning muud esmased peavalud. 
Need neli suurt kategooriat hõlmavad omakorda mitmeid erinevaid nimetatud 
peavalude alatüüpe ning ka iseseisvaid diagnostilisi üksusi (Rahvusvahelise Pea-
valude Seltsi Peavalude Klassifikatsiooni Komitee, 2018). 
Esmased peavalud põhjustavad märkimisväärset isiklikku kannatust ning 
elukvaliteedi langust, kuid on olulised mõjutajad ka rahvatervise seisukohast ning 
arvestatava ühiskondliku koorma allikaks (Steiner jt, 2014; Global Burden of 
Disease, 2015; Messali jt, 2016; Saylor ja Steiner, 2018). Migreen ja pingetüüpi 
peavalu on mõlemad kuue kõige levinuma haiguse hulgas maailmas ning migreen 
on teisel kohal puudega elatud aastate põhjusena (Vos jt, 2017). 
Epidemioloogilise uurimustöö tulemused loovad aluse haigusmustrite, haigu-
sest põhjustatud isikliku ja ühiskondliku koormuse ja maksumuse ning tervis-
hoiusüsteemi vajaduste hindamiseks ühiskonnas (Steiner jt, 2013; Stovner jt, 
2014). Esmaste peavalude epidemioloogiat puudutavaid andmeid on maailmas 
viimasel kahel aastakümnel järjest rohkem kogunenud (Stovner jt, 2007; Stovner 
ja Andree, 2010; Maailma Tervishoiu Organisatsioon ja Lifting The Burden, 2011; 
Saylor ja Steiner, 2018), kuid mõnes regioonis on tühimikud ikkagi märgatavad. 
Kõikide peavalude keskmine aastane levimus Euroopas hinnatakse 53%-le, 
migreeni keskmine aastane levimus on 14,7% ja pingetüüpi peavalul 62,6% 
(Stovner ja Andree, 2010). Trigeminaalautonoomsete tsefalalgiate aastane levi-
mus on siiani avaldatud andmetel 0.05% (Fischera jt, 2008) ning kõikidel muudel 
esmastel peavaludel 1,7% (Schwaiger jt, 2008). Eesti kohta ei ole esmaste pea-
valude levimuse andmeid varem avaldatud. 
Suured populatsioonipõhised epidemioloogilised uuringud on tavaliselt 
ressursi- ning ajakulukad (Stovner jt, 2014). Samas on praegune kiire digiühis-
konna areng loomas potentsiaalseid eeldusi otsimaks alternatiivseid epidemio-
loogilistes uuringutes rakendatavaid veebipõhiseid meetodeid, mis võimaldaksid 
järjest avarduvaid infotehnoloogilisi võimalusi kasutades aja- ning ressursimahtu 
vähendada. Kindlasti oleks selline lähenemine võimalik peavalude epidemio-
loogilistes uuringutes, arvestades, et enamike esmaste peavalude puhul on võima-
lik peavalu tüüpi määrata uuritava kaebuste ning anamneesi alusel ilma instru-
mentaalsete uuringute vajaduseta (Mitsikostas jt, 2015). 
Eesti on maailmas üks juhtivaid riike interneti ning veebipõhiste lahenduste 
kasutamise osas kodumajapidamises (Rahvusvaheline Telekommunikatsiooni 
Liit, 2017). 2019. aastal oli Eesti Euroopa Liidu liikmesriikide seas kaheksandal 
kohal digitaalse majanduse ja ühiskonna indeksi poolest (Euroopa Komisjon, 
66 
2019), mis on näitaja, mis arvestab Euroopa riikide digitaalse soorituse erinevaid 
tahke nagu digitaalne ühenduvus, inimeste digitaalne hõlmamine ja oskused, 
veebiteenuste kasutamine, digitaalse tehnoloogia integratsioon ühiskonnas ning 
digitaalsed avalikud teenused. 
Nimetatud asjaolud loovad head eeldused katsetamaks veebipõhise lähene-




Antud uurimustöö eesmärkideks olid esmaste peavalude epidemioloogilise 
uurimuse jaoks diagnostilise küsimustiku koostamine ning testimine, esmaste 
peavalude aastase levimuse määramine 20–64-aastaste täiskasvanute seas Eestis 
ning veebipõhise lahenduse kohaldatavuse hindamine peavalude epidemioloogia 
alases uurimistöös, võrreldes veebipõhiselt teostatud uuringu ning populat-
sioonipõhise epidemioloogilise uuringu tulemusi. 
 
Uuritavad ja meetodid 
Uurimustöö kiitis heaks Tartu Ülikooli inimuuringute eetika komitee (load nr. 
242T-11 ja nr. 252T-15). Kõik uuritavad andsid kirjaliku või digitaalse infor-
meeritud nõusoleku uuringus osalemiseks. 
 
1. Peavalude epidemioloogilise uuringu küsimustiku koostamine ja testimine 
(I artikkel) 
Koostati veebipõhine peavalude küsimustik koos diagnostilise algoritmiga. 
Viimane tugines Rahvusvahelise Peavalude Klassifikatsiooni 3. beetaversiooni 
diagnoosikriteeriumitele ning selle eesmärgiks oli küsimustiku vastuste alusel 
diagnoosida enamusi esmaseid ja üksikuid teiseseid peavalusid. Kõiki 18–65 
aasta vanuseid patsiente, kellel oli Tartu Ülikooli Kliinikumi peavalukliinikus 
peavaluarsti poolt veebruarist 2014 kuni märtsini 2015 diagnoositud kindlat tüüpi 
peavalu, paluti küsimustikku täita. Algoritmi poolt pakutud peavalu diagnoosi 
võrreldi peavaluspetsialisti poolt püstitatud diagnoosiga, et hinnata küsimustiku 
ja algoritmi sensitiivsust, spetsiifilisust, postiivset ja negatiivset ennustusväärtust. 
 
2. Esmaste peavalude aastane levimus 20–64-aastastel täiskasvanutel Eestis 
(II artikkel) 
2016. aasta jaanuarist kuni 2017. aasta maini läbi viidud uuringus kasutati 
Eesti rahvastikuregistrist saadud 3000 uuritavaga juhuvalimit, mis oli soo, 
vanuse, elukoha (maal või linnas) ning perekonnaseisu järgi kihitatud ning vastas 
Eesti üldpopulatsiooni vastavatele näitajatele. Uuritavad olid 20–64-aastased 
ning elasid Tartu linnas või Tartu maakonnas. Uuritavatega kontakteerusid 
eelnevalt uuringu metoodika osas koolitatud meditsiiniteaduste valdkonna üli-
õpilased, kes palusid uuritavatel kas telefonitsi või näost näkku vastata eelnevalt 
kirjeldatud peavaluküsimustikule. Uuritaval lubati kirjeldada kuni kolme kõige 
tülikamat peavalu tüüpi. Küsimustikke analüüsis neuroloog, kes saadud vastuste 
alusel ning Rahvusvahelise Peavalude Klassifikatsiooni kolmanda beetaversiooni 
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kriteeriumitele toetudes määras peavalu kirjeldanud uuritavate peavalu tüübi. 
Eristati järgmisi diagnoosikategooriaid: episoodiline ja krooniline migreen, epi-
soodiline ja krooniline pingetüüpi peavalu, krooniline igapäevane peavalu (pea-
valu ≥15 päeval kuus), trigeminaalautonoomsed tsefalalgiad ning muud esmased 
peavalud. Kirjeldatud peavalu pidi täitma eelmainitud kategooriate kindlaid või 
võimalikke diagnoosikriteeriume. Kui peavalu ei täitnud ühegi kategooria 
tingimusi, diagnoositi teadmata peavalu. Uuringu valimit kaaluti uuritavate 
vanust, sugu, elukohta, haridustaset ning perekonnaseisu arvestades, et uuringu 
valim vastaks demograafiliste andmete osas Eesti üldpopulatsioonile. Saadud 
tulemuste alusel kalkuleeriti esmaste peavalude aastane levimus 20–64-aastastel 
täiskasvanutel Eestis. 
 
3. Veebipõhise lahenduse rakendatavus esmaste peavalude epidemioloogilises 
uurimistöös (III artikkel) 
Eelnevalt kirjeldatud veebipõhist peavaluküsimustikku kasutades viidi 2016. 
aasta jaanuarist kuni 2017. aasta maini läbi internetipõhine uuring 20–64-aastaste 
Eesti kodanike seas. Uuritavad värvati interneti teel, teavitades neid küsimus-
tikust Eesti digitaalses kogukonnas kõige populaarsemate portaalide ning 
150 000 e-maili kaudu. Saadud valimis arvutati esmaste peavalude aastased 
levimused, mida võrreldi eelnevalt kirjeldatud populatsioonipõhises uuringus 





1. Peavalude epidemioloogilise uuringu küsimustiku koostamine ja testimine 
(I artikkel) 
Koostatud küsimustiku ja diagnostilise algoritmi spetsiifilisus ja sensitiivsus 
põhiliste diagnostiliste kategooriate suhtes, rakendades Rahvusvahelise Pea-
valude Klassifikatsiooni kolmanda beetaversiooni kindla peavaludiagnoosi 
kriteeriume, oli järgmine: kogu migreeni suhtes 0,97 ja 0,56; kogu pingetüüpi 
peavalu suhtes 0,92 ja 0,52; trigeminaalautonoomsete tsefalalgiate suhtes 1 ja 0,5 
ning muude esmaste peavalude suhtes vastavalt 0,98 ja 0,5. Peale võimalike 
peavaludiagnooside kriteeriumite kaasamist diagnostilisse algoritmi peamiste 
epidemioloogilistes uuringutes huvipakkuvate kategooriate jaoks küsimustiku ja 
algoritmi spetsiifilisus märkimisväärselt ei langenud, kuid sensitiivsus suurenes 
oluliselt. Peale võimalike kriteeriumite kaasamist oli küsimustiku ja algoritmi 
sensitiivsus migreenile 0,8 ning pingetüüpi peavalule 0,6 ning spetsiifilisus 
migreenile 0,9 ja pingetüüpi peavalule 0,92. 
 
2. Esmaste peavalude aastane levimus 20–64-aastastel täiskasvanutel Eestis 
(II artikkel) 
3000-liikmelisest valimist saadi kontakti 2162 uuritavaga, kellest omakorda 
1215 (56%) vastasid peavaluküsimustikule. Neist 502 (41%) kirjeldasid peavalu 
esinemist eelneva aasta jooksul. Vanusele, soole, haridustasemele, perekonna-
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seisule ja elukohale kaalutud üheaastased levimused olid esmaste peavalude osas 
järgmised: kogu peavalu 41,0%, kogu migreen 17,7%, kogu pingetüüpi peavalu 
18,0%, trigeminaalautonoomsed tsefalalgiad 0,4%, muud esmased peavalud 
2,5% ja krooniline igapäevane peavalu 2,7%. 
 
3. Veebipõhise lahenduse rakendatavus esmaste peavalude epidemioloogilises 
uurimistöös (III artikkel) 
Veebipõhist küsimustikku täideti 5347 uuritava poolt 5708 korda. Uurita-
vatest 3896-l (72,9%) eelnenud aasta jooksul peavalu ei esinenud, 1346-l uuri-
taval esines üht tüüpi peavalu ning 15 (0,3%) uuritavat kirjeldasid enam kui ühte 
tüüpi peavalu. Uuringu valimi demograafilised näitajad erinesid statistiliselt 
oluliselt Eesti 20–64-aastasest populatsioonist, seetõttu kaaluti uuringu valimit 
vastavalt eale, soole, haridustasemele, perekonnaseisule ning elukohale (maal või 
linnas). Peavalu all kannatavate uuritavate proportsioon (23,1%) oli veebipõhise 
uuringu valimis väiksem võrreldes populatsioonipõhises uuringus leituga 
(41,0%). Samas erinevate kaalutud peavaludiagnooside proportsioonid pea-
valuga uuritavate seas olid mõlemas uuringus valdavas osas sarnased – krooniline 
migreen 2% ja 2%, krooniline pingetüüpi peavalu 4% ja 4%, trigeminaalauto-
noomsed tsefalalgiad 1% ja 1%, muud esmased peavalud 6% ja 5% ning teadmata 
peavalud 5% ja 3% vastavalt populatsioonipõhise ja veebipõhise uuringu peavalu 
kaalutud diagnoosidest. Erinevus esines ainult episoodilise migreeni osas, mida 
oli veebipõhises uuringus vähem (31% versus 42%), ning episoodilise pingetüüpi 
peavalu osas, mida oli veebipõhises uuringus rohkem (54% versus 41%) kui 





1. Uurimustöö käigus koostatud ja testitud peavaluküsimustikul oli rahuldava 
väärtusega spetsiifilisus ja sensitiivsus migreeni ning pingetüüpi peavalu diag-
nooside osas, kasutamaks küsimustikku edasises primaarsete peavalude epi-
demioloogilises uurimistöös. Uuringu käigus kinnitus, et peavalude epidemio-
loogia alastes küsimustikes peaks peavalude diagnoosimisel rakendama nii 
Rahvusvahelise Peavalude Klassifikatsiooni kindla kui ka võimaliku diagnoosi 
kriteeriume, kuna nõnda suureneb küsimustiku sensitiivsus ning ei teki peavalude 
levimuse alahindamist. 
 
2. Uurimustöös leitud esmaste peavalude aastased levimused 20–64-aastaste 
täiskasvanute seas Eestis on sarnased varasemalt avaldatud levimuse näitajatega 
teistes Euroopa riikides, välja arvatud episoodilise pingetüüpi peavalu osas. Epi-
soodilise pingetüüpi peavalu madal levimus antud uuringus on suure tõe-
näosusega alahinnatud. Uurimuse tulemused viitavad, et nagu ka teistes Euroopa 
riikides, on esmased peavalud Eestiski oluliseks haigestumise, elukvaliteedi 
languse ning ühiskondlik-majandusliku koormuse põhjuseks. 
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3. Uurimuse tulemused näitavad, et veebipõhine peavalualane epidemioloogiline 
teadustöö tuleb arvesse kui potentsiaalne aja- ja ressursisäästlik meetod nendes 
riikides, mis on infotehnoloogiliselt kõrgesti arenenud ning kus interneti ja 
veebipõhiste rakenduste kasutamine on üldpopulatsioonis laialt levinud. Selline 
lähenemine võimaldab koguda suuri uuringuvalimeid suhteliselt lühikese aja 
jooksul. Lisaks pakuvad infotehnoloogilised lahendused uuritavate identifitseeri-
mismeetodeid, mis väldivad andmete kontaminatsiooni, ning tööriistu digi-
taalsete küsimustike näol, mis suudavad erinevaid peavaludiagnoose rahuldavalt 
eristada. Möödapääsmatu on edasine uurimistöö veebipõhise metoodika edasi-
arendamiseks, leidmaks usaldusväärseid valimi moodustamise ning uuritavate 
värbamise viise, et saavutada esinduslikke valimeid ning vältida kallutatust ning 
kõige tõenäolisemalt peavalude levimuse alahindamist veebipõhises epidemio-
loogilises uurimustöös.  
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11. APPENDICES 













• Treeningtundide arv nädalas 
• Suitsetamine (mitu sigaretti päevas?) 
• Viimase aasta jooksul tarbinud kohvi keskmiselt … tassi päevas 
• Kui sageli viimase aasta jooksul keskmiselt tarbisite alkohoolseid jooke (õlu, vein, 
viin jt): 
o Mitte kunagi/väga harva 
o 1–3 korda kuus 
o 1 kord nädalas 
o 2–4 korda nädalas 




Kas Teil on viimase aasta jooksul esinenud KORDUVAID peavalusid, mis EI OLNUD 
tingitud ägedast nakkushaigusest, tarvitatud ravimi(te) kõrvaltoimest, meditsiinilisest 
protseduurist või toksilis(t)e aine(te)ga kokkupuutumisest (k.a. alkohol ja selle järgne ehk 




Järgnevalt palume Teil kirjeldada oma tüüpilist peavalu nii täpselt kui võimalik, vastates 
allolevale 14 küsimusele ja nende alaküsimustele. Kui Teil esineb mitut erinevat tüüpi 
peavalusid, siis palun täitke iga peavalu tüübi kohta sama küsimustik eraldi. 







g. Silm, selle ümber ja taga 
h. Kogu pea 
i. Juustega kaetud kuni 6 cm suurune muutumatu ala 
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2. Peavalu poolsus 
a. Peavalu esineb mõlemal peapoolel korraga 
b. Peavalu asub ühel peapoolel 
i. Ainult paremal 
ii. Ainult vasakul 
iii. Vaheldumisi kas paremal või vasakul 
3. Valu iseloom 
a. Suruv, pressiv, pigistav, tuim 
b. Tuikav, pulseeriv 
c. Lõikav, torkiv 
d. Sähviv, elektrilöögitaoline 
4. Valu tugevus 0–10 palli süsteemis, kus 0 on valu puudumine, 10 on kõige tugevam 
võimalik valu üldse 
5. Kas valule eelnevad (kuni 1 tund enne valu algust) või koheselt koos valu algusega 
(kestvusega kuni 1 tund) tekivad muud sümptomid/kaebused? 
a. Ei 
b. Jah: 
i. nägemishäired (v.a. topeltnägemine) 
ii. naha tundlikkuse häired (tuimus, „sipelgate jooksmine“, „nõelte torkimine“ 
jms) 
iii. kõnetakistus 
iv. ühe kehapoole nõrkus 
v. pudistav kõne 
vi. pearinglus 














iii. Valguse talumatus 
iv. Müra talumatus 
v. Lõhnade talumatus 
vi. Tavapäraste igapäevaste füüsiliste tegevuste talumatus või nende vältimine 
vii. Rahutus, erutus, püsimatus 
viii. Valuga sama peapoole: 
 silma punetus ja/või pisaravool 
 ninakinnisus ja/või vedel eritis 
 silmalau turse 
 otsmikupiirkonna/näo higistamine 
 otsmikupiirkonna/näo punetus 
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 „lukus“ tunne kõrvas 
 pupilli kitsenemine ja/või silmalau allavaje 
ix. Valuga samapoolne näotuimus 
7. Ühe valuhoo tavaline kestvus (juhul, kui ei tarvitata valuvaigisteid või valu nendele 
ei allu) on … sek/min/h/päeva kuni … sek/min/h/päeva. 
8. Peavalu hoogude keskmine sagedus on … hoogu päevas/kuus/aastas. 
a. Peavalu oli esimesest päevast igapäevane ja pidev, pole olnud valuvabu perioode 
i. Jah 
ii. Ei, aga peavalu esineb rohkem kui 1 päeval kuus 
iii. Ei, aga peavalu esineb harvem kui 1 päeval kuus 
iv. Peavaluga päevade arv kuus on ... 
b. Kui peavalud esinevad järjestikuste hoogude ehk „kobaratena“, siis need perioodid 
kestavad keskmiselt … päeva/nädalat ning nende perioodide valuvaba vahe on 
i. Lühem kui 1 kuu 
ii. Pikem kui 1 kuu 
c. Kas indometatsiini kasutamine täielikult ennetab hoogusid? 
i. Jah 
ii. Ei 
iii. Ei ole indometatsiini tarvitanud 




ii. Füüsiline pingutus või vahetult peale seda 
iii. Seksuaalne aktiivsus (peavalu süveneb koos seksuaalse erutusega ja/või tekib 
järsku vahetult enne või orgasmi ajal) 
iv. Külma joogi/söögi tarbimine ja/või peapiirkonna kokkupuude külmaga 
v. Lennukiga reisimise ajal. Valu tekib: 
 lennuki õhku tõusmisel 
 lennuki maandumisel 
 lendamisel saavutatud stabiilsel lennukõrgusel 
vi. Uni 
10. Kas Teie peavalusid võivad esile kutsuda mingisugused välistegurid? 
a. Ei 
b. Jah 
i. Teatud toidud või joogid (v.a. alkohol) 
ii.  Alkohoolsed joogid 
iii. Toitumiskordade vahelejäämine, nälg 
iv. Vedelikupuudus, janu 
v. Vaimne pinge/stress 
vi. Füüsiline pingutus/stress 
vii. Sundasendid 
viii. Arvutimonitori ja/või teleekraani jälgimine 
ix. Unerežiimi muutused 
x. Ilmastiku muutused 
xi. Menstruatsioon 
xii. Näo teatud punktide katsumine, nendele vajutamine 
xiii. Hammaste pesemine 
xiv. Toidu mälumine 
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xv. Reisimine kõrgmäestiku piirkondades 
xvi. Muu 
11. Peavalu hoogude tekkimisel olen viimase 3 kuu jooksul tarvitanud selle vastu 
valuvaigisteid: 
a. Ei tarvita 
b. Jah, tarvitan harvemini kui 1 päeval kuus 
c. Jah, tarvitan sagedamini kui 1 päeval kuus 
Valige rippmenüüst Teie poolt tarvitatav(ad) ravim(id). 
 Mitmel päeval kuus Te tarvitate mitut erinevat valuvaigistit samal päeval? 
12. Peavalud esinevad mul alates … eluaastast. 
13. Kas Teil on kunagi esinenud peatraumat? 
a. Ei 
b. Jah 
i. Peavalu tekkis … tundi/päeva/kuud/aastat peale vigastust 
ii. Peavalu esines juba enne peatraumat 
14. Kas te olete oma peavalude tõttu pöördunud 
a. perearstile 
b. neuroloogile 




o Luban minu peavalude põhjuste täpsemaks selgitamiseks võtta minuga ühendust 
peavalu arstidel. Olen teadlik, et sellisel juhul muutuvad minu isikuandmed arstile 
nähtavateks. 
o E-maili teel: ……………@................. 
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